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Abstract: To date, vaccination has become one of the most effective strategies to control and reduce
infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were developed
as live-attenuated or inactivated pathogens, and, although they still represent the most extended
human vaccine types, they also face some issues, such as the potential to revert to a pathogenic form
of live-attenuated formulations or the weaker immune response associated with inactivated vaccines.
Advances in genetic engineering have enabled improvements in vaccine design and strategies, such
as recombinant subunit vaccines, have emerged, expanding the number of diseases that can be
prevented. Moreover, antigen display systems such as VLPs or those designed by nanotechnology
have improved the efficacy of subunit vaccines. Platforms for the production of recombinant vaccines
have also evolved from the first hosts, Escherichia coli and Saccharomyces cerevisiae, to insect or
mammalian cells. Traditional bacterial and yeast systems have been improved by engineering and
new systems based on plants or insect larvae have emerged as alternative, low-cost platforms. Vaccine
development is still time-consuming and costly, and alternative systems that can offer cost-effective
and faster processes are demanding to address infectious diseases that still do not have a treatment
and to face possible future pandemics.
Keywords: vaccine; protein expression system; alternative platform; subunit; recombinant antigen
1. Historical Perspective of Vaccine Development
Although attempts to prevent small-pox infection by variolation was reported in
the 15th century in China [1], it was not until 1796 that Edward Jenner identified that
inoculation of humans with cowpox virus was protective against subsequent smallpox
infection, leading to the development of the first world vaccine [2]. The term vaccine was
thus originated after the Latin word vacca, which means cow [3]. This finding opened
the era of vaccination and led to the discovery of further vaccines against other infectious
diseases. In 1879 Louis Pasteur established the concept of attenuated microorganisms while
studying chicken cholera Pasteurella multocida [4] and in 1885, based on the discovery of
the infectious agent of rabies by Pierre Galtier he also developed a vaccine for humans
using an attenuated strain [5]. The finding of attenuated microorganisms defined the
beginning of the first golden age of vaccinology (from Pasteur’s era to 1938), leading to
the development of other vaccines, such as live-attenuated (tuberculosis and yellow fever),
inactivated (typhoid, cholera, plague and pertussis) and subunit vaccines (tetanus and
diphtheria) [6]. Influenza vaccines were developed in the mid-1930s, after identifying that
influenza virus could be grown in embryonated eggs, implementing a method that is still
used today to manufacture most of influenza vaccines [7]. One of the main limitations
in the development of vaccines was the lack of techniques to culture infectious agents,
such as viruses, that need host tissue to grow [8]. Advances in culture techniques defined
a landmark success in the second golden age of vaccinology (1940–1970), leading to the
development of vaccines for viral infections such as poliomyelitis, measles, mumps and
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rubella [6]. In the early 1970s, advancements in molecular biology led to the development
of recombinant DNA technology [9], and over the next 50 years, recombinant expression
systems such as Escherichia coli (E. coli), Saccharomyces cerevisiae (S. cerevisiae) or baculovirus–
insect cells were stablished for foreign protein production, leading to the third phase of
vaccine development and the emergence of subunit vaccines [8]. The first subunit vaccine
against hepatitis B virus (HBV) was approved in 1986 and was based on the viral surface
protein that self-assembled into VLPs using S. cerevisiae as expression system [10]. Vaccine
design focused on the use of specific antigens from infectious agents, including those
that were unable to culture or were highly pathogenic, and recombinant vaccines such as
human papillomavirus (HPV) were also developed. Over the last years, advances in genetic
engineering have enabled the development of new platforms for protein expression, such
as mammalian cells, plants or insect larvae, and also the emergence of new technologies
applied to vaccine development, such as nanotechnology.
Nowadays, there are vaccines available to protect against more than 20 human dis-
eases, and the World Health Organization (WHO) estimates that vaccines save between
4 million and 5 million lives every year [11]. Although the market value of veterinary
vaccines is modest when compared to human counterparts, veterinary vaccination has also
seen many significant advances in technologies over the last years. What is more, many new
vaccine technologies may find their first commercial application in veterinary market, and
this is reason why veterinary vaccines are more varied. In addition to traditional vaccines
based on whole-pathogens and subunit vaccines, new vaccines technologies, such as live
genetically modified pathogens, vectored vaccines (that use viruses as delivery systems for
foreign antigens) and DNA vaccines, are already approved for their commercialization [12].
The One Health approach has emerged in the recent decades as a new perspective
within vaccination strategies. It is a transdisciplinary approach that recognizes the impor-
tance of the interconnection between people, animals, plants and their shared environment.
One Health issues include several topics related with health threats such as zoonotic
diseases, antimicrobial resistance and food safety, among others. Regarding vaccination,
zoonotic diseases are of great importance, because they can spread between animals and
people, as is the case of Ebola, rabies or West Nile virus. For example, the One Health
approach for Ebola aims for a shared benefit, i.e., the vaccination of wild apes in order to
protect both apes and human [13].
2. Key Aspects in Vaccine Design
2.1. The Immune System and the Rationale of Vaccination
Infectious-disease vaccines are based on the controlled exposure to an infectious
agent, either whole-cell or specific antigen, with the aim to induce an immune response.
The immune system is composed of two different arms, the innate immune system that
includes a diverse array of cell types that interact with foreign molecules in a nonspecific
manner and the adaptive immune system that, on the contrary, interacts in a specific
manner through humoral and cellular responses [8]. The adaptive immune response
depends on the interaction of three key cell types: antigen-presenting cells (APCs), thymus-
derived lymphocytes (T cells) and bone-marrow-derived lymphocytes (B cells) [3]. Cellular
immune response is based on the action of T cells, while humoral immune response
involves the activity of antibodies generated by B cells. APCs are specialized in the capture
of antigens, subsequent processing and presentation on their surface bounded to a Major
Histocompatibility Complex (MHC) I or II for T-cells recognition. B-cell receptors may
directly recognize foreign antigens, leading to the production of subclasses of antibodies [3].
Nonetheless, T cells are unable to directly interact with antigens and the mechanism of
MHC presentation in addition to appropriate signaling plays a key role in cell activation
and is of particular importance in vaccine development in which a T-cell-mediated response
is required [14]. T cells are composed by cytotoxic T cells (CTLs) that mediate lysis of
autologous cells infected by intracellular pathogens and T helper cells (Th) that are able to
stimulate cells of both the innate and adaptive immune system through the secretion of
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cytokines [8] and also by cell-to-cell interactions (e.g., CD40/CD40L). Based on the profile
of the secreted cytokines the responses are classed as T helper 1 (Th1) or T helper 2 (Th2).
Th1 response stimulates a cellular based immune response, while Th2 response leads to
a humoral immune response [8]. Vaccines are highly dependent on effective adaptive
immune responses, and although traditionally strategies for vaccines production have
focused on the induction of strong humoral response, currently, a vaccine candidate that
has a balanced Th1/Th2 response is considered optimal [15].
Subunit vaccines have advantages over whole-organism vaccines regarding safety
and production but in general they tend be less immunostimulatory [16]. This is possibly
caused by a reduced ability to crosslink B-cell receptors, as well as a reduced ability to
stimulate APCs [17]. Many approaches have been explored to develop more effective
subunit vaccines, including the use of adjuvants to stimulate the immune system or the
use of nanotechnology to design and generate effective antigen display systems.
2.2. Route of Administration
The route of administration is an important issue for the achievement of an adequate
protection by vaccination. Most of available vaccines are based on the injectable route
of administration, either intramuscular or subcutaneous, that is known to elicit a robust
systemic humoral response but confers a weaker T-cell-mediated immunity and mucosal
protection [18,19]. In addition to limitations related to immunity, injectable vaccines also
require trained personnel for administration and can cause inconveniences to patients.
Vaccine methods delivered to the mucosal interface or intradermally are being explored
as attractive alternative to needle-based delivery systems, as they are painless and can be
self-administered.
Given that a majority of pathogens invade via mucosal surfaces, delivery of vaccines
across mucosal surfaces is of great interest to provide immunity at early stages of infection
before pathogens are able to cause a widespread infection [20]. A wide range of mucosal
vaccination routes are being explored, with oral and intranasal being the most common.
Others include ocular, intravaginal and intrarectal [20]. They are also promising candidates
to improve overall immunogenicity as vaccination at mucosal surfaces can induce mucosal
antibodies (IgA) and cell-mediated immune responses, while still producing a systemic
antibody response (IgG) [21–24]. Current marketed oral vaccines are based on attenuated
pathogens [25], still bearing the potential to revert to pathogenic forms [26] and new
approaches for the development of safer oral vaccines are demanded. The use of food-grade
organisms can offer several advantages for oral vaccines as they can be used at the same
time for antigen expression and oral delivery, avoiding costly purification processes [27]
and providing stability when orally administered. The development of efficient oral
vaccines involves several key aspects, such as the viability/bioactivity when stored at
ambient temperature, the characterization of the adjuvant activity of the expression hosts
and the balance between immunogenicity and tolerance [27]. The organisms currently
used for this purpose are bacteria (Lactobacillus and Bacillus), yeasts, insects, plants and
algae [27].
The only licensed intranasal vaccine for use in humans is for influenza (FluMist®
Quadrivalent; AstraZeneca, Cambridge, UK) and consists of a live attenuated form of the
virus. The nasal cavity is highly vascularized with a large surface area for antigen uptake;
however, most antigens have very little affinity for the nasal epithelium, leading to a fast
clearance [28]. To solve this issue, researchers are focusing on improving nasal delivery
methods [29].
Another vaccine delivery route capable of triggering both systemic and mucosal im-
munities is the intradermal route. The skin is composed of a large number of immune cells
conforming a great target location for vaccine administration [30]. Recent advancements
have led to the development of techniques and instruments that can overcome the diffi-
culties associated with intradermal administration [31]. Among them, solid microneedles,
particle injectors and self-administrable patches with coated microprojections or biodegrad-
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able needles have been developed [32]. Intradermal vaccination has also been of interest for
its ability to elicit equivalent antibody responses at lower doses, a phenomenon typically
described as dose sparing [33]. Lowering a vaccine dose could be of great importance for
pandemics as huge quantities of doses are required. In this regard, the US Food and Drug
Administration (FDA) approved the trivalent inactivated intradermal influenza vaccine
for use during the 2012–2013 season, and a quadrivalent formulation was subsequently
approved in 2014 [34].
3. New Strategies for Vaccine Development
Classical vaccines of whole-pathogen antigens have been irrefutably successful in the
control of many of the important veterinary and human infectious diseases but they also
possess some limitations and associated potential problems. Although live-attenuated vac-
cines can induce a robust immune response, they bear the risk of retaining virulence, [35]
and although inactivated vaccines are a safer alternative, they usually produce less im-
munity and need multiple boosters [36,37]. In addition, the production of these vaccines
usually requires high-level biosafety facilities implying high production costs. Modern
vaccine technologies can overcome these manufacturing issues and generate safer vaccines
rapidly and at a low cost. Different strategies for vaccines development include the use of
viruses, viral vectors, nucleic acids, proteins or cells [38,39].
Approved vaccines for human use mostly fall into the virus-based and the recombinant-
protein-based categories. Among all approaches to develop a vaccine candidate against
the emerging coronavirus disease 19 (COVID-19) pandemic, two new types of platforms,
mRNA-based and viral-vector-based vaccines have been the first to reach the market due
to the rapid advancement in their methodologies [40]. Veterinary vaccines are more var-
ied and along with traditional virus-based and recombinant-protein-based vaccines, live
genetically modified, viral vector and DNA vaccines are already in the market [14]. New
technology vaccines can also be used as a valuable tool in disease control and eradication
programs in animal health by enabling the immunological differentiation between infected
and vaccinated animals. These vaccines termed as marker or DIVA (differentiating infected
from vaccinated animals) are usually based on recombinant deletion mutants of wild-type
pathogens or subunit vaccines [38] and are of great interest in disease control, because
they allow us to use serological surveillance for the presence of infection after vaccination.
Infection and vaccination can be detected by the use of companion diagnostic tests such as
enzyme linked immunosorbent assays (ELISA). DIVA vaccines have been widely used for
the control of pseudorabies and classical swine fever (CSF) in pigs and infectious bovine
rhinotracheitis in cattle [41].
3.1. Pathogen-Based Vaccines
These vaccines consist of the pathogen that causes the infectious disease either in
their whole form (as live-attenuated or inactivated pathogens) or as derived split-products
(subunit vaccines). Pathogens used as vaccine candidates are viruses, bacteria or para-
sites, with viruses and bacteria being the predominant types in current marketed vaccines.
Live-attenuated and inactivated formulations are still the most widely used to date in
human health [38]. The advantages of these methods include well-developed methodolo-
gies, well-established regulation policies and existing manufacturing facilities [39]. On the
contrary, production of large volumes of pathogens is required, and it demands specialized
containment facilities and poses considerable risk to the operators and environment due
to the infectious nature of the material [42,43], involving high costs of manufacturing. In
addition, manufacturing process is lengthy with large periods until vaccine delivery [44].
Live-attenuated vaccines most closely mimic natural infections, eliciting strong cellular
and antibody responses [8], but they also pose risks of uncontrolled replication and have
the potential to revert to a pathogenic form [45]. Advancements in genetic engineering
have reduced the unpredictability of experimental attenuation and improved the safety as-
sociated with live-attenuated pathogens [46]. Killed vaccines consist of the disease-causing
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pathogen inactivated by chemicals, heat or radiation [45]. They cannot replicate and are
safer than live vaccines, but they usually prompt a weaker immune response, and, generally,
additional doses or booster shots are required to maintain protection [47,48]. In addition to
whole-pathogen vaccines, split-products or subunit vaccines can also be generated from
natural sources; however, they tend to reduce immunogenicity when compared with whole
formulations [38]. Split-products can be composed of the infectious agent disassembled
into its component parts or only on selected components, also known as subunit vaccines.
They can be divided into four main categories: protein-based, polysaccharides, conjugates
and toxoids [45]. Protein-based subunit vaccines use specific isolated proteins as antigens
and in addition to purification from natural sources, they can be produced as heterologous
proteins in recombinant systems. As a key aspect of this review, recombinant-protein-based
vaccines and the platforms for protein expression will be further detailed within this work.
Bacterial subunit vaccines can be divided into toxoid vaccines (detoxified toxins) and
capsular polysaccharides vaccines. A variation of them are conjugate vaccines, consisting
of an antigen (often the bacterial polysaccharides) covalently attached to a carrier protein
(e.g., tetanus or diphtheria toxoid), to improve the immunogenicity of the antigen [49].
Virus-derived lipids (virosomes) are also of great interest for vaccine development.
The envelope fraction containing lipids and membrane-associated viral proteins is purified
from enveloped viruses and is assembled in vitro for presenting antigens from different
pathogens that can be either displayed on the virosome surface or incorporated into its lu-
men [50]. While virosomes containing envelope proteins from a wide range of viruses have
been generated, only virosomes incorporating hemagglutinin (HA) and neuraminidase
proteins from the influenza viral envelope have been licensed as human vaccines. Two dif-
ferent virosomes were approved for human health, Inflexal®, an influenza vaccine, [51] and
Epaxal®, a formalin inactivated hepatitis A that is adsorbed to an influenza virosome [52];
however, in 2011, Crucell decided to discontinue these vaccines from the market [53]. Bac-
terial outer membrane vesicle (OMVs) have also attracted the attention as vaccine platform
against bacterial pathogens. OMVs are naturally released from Gram-negative bacteria
and are composed of the outer membrane that contains key antigenic components required
to elicit a protective immune response. Genetically manipulated bacteria to increase OMV
are known as GMMA (Generalized Modules for Membrane Antigens) and can be further
manipulated for overexpression of homologous or heterologous protein antigens, which
can serve as vaccine antigens [54]. This system have allowed the development of Meningo-
coccal group B Vaccines for human (Bexsero®; GSK, Londres, UK), based on the expression
of Neisseria meningitidis cell surface antigens in E. coli in combination with outer membrane
vesicles (OMV) from the bacterial membrane of Neisseria meningitidis serogroup B.
3.2. Viral-Vector-Based Vaccines
Viral vector vaccines work by cloning the antigen of interest into a heterologous virus
that will serve as a vector to deliver the foreign gene inside the host cells, leading to its
expression [55]. They often provide long-lived immunity, including humoral antibodies,
secretory antibodies and cytotoxic T cells [38]. Adenoviruses are the most extended for
human vaccines because they are infectious to various cell types, and they show efficient
transgene expression, high in vitro growth, lack of genome integration and genetic sta-
bility [56]. A common obstacle is the host’s preexisting immunity to certain vectors that
could mitigate the efficacy of the vaccine [39]. The use of alternative vectors that have low
seroprevalence in the host may circumvent anti-vector immunity [57–59]. The number of
viral vector vaccines approved thus far for human use is still limited. The first viral-based
vaccine approved for human use was Ervebo® (Merck & Co., Kenilworth, NJ, USA), a
vaccine against Ebola based on a recombinant vesicular stomatitis virus with a deletion
in the envelope glycoprotein replaced with the Zaire Ebola virus (ZEBOV) surface glyco-
protein (rVSV∆G-ZEBOV-GP). A second Ebola vaccine was also approved consisting of
two components, Zabdeno® that is given first and Mvabea® that is administered approxi-
mately eight weeks later as a booster (Janssen; Johnson & Johnson; New Brunswick, NJ,
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USA). Zabdeno® (Ad26.ZEBOV) is a recombinant Adenovirus type 26 (Ad26) encoding the
ZEBOV glycoprotein while Mvabea® (MVA-BN-Filo) is a recombinant Modified Vaccinia
Ankara Bavarian Nordic Virus encoding the ZEBOV glycoprotein. Furthermore, four viral
vector vaccines were recently approved in different countries for treatment of pandemic
COVID-19 disease. Vaxzevria® (AstraZeneca, Cambridge, UK and Oxford University,
Oxford, UK) is based on a replication-deficient chimpanzee adenovirus (ChAdOx1) that
contains the genetic material of the SARS-CoV-2 virus spike protein (ChAdOx1-SARS-CoV-
2). COVID-19 Vaccine Janssen (Janssen, Johnson & Johnson) is based on a recombinant
replication-incompetent adenovirus type 26 (Ad26) that contains the sequence that encodes
the spike protein (S) of the SARS-CoV-2 (Ad26.COV2-S). Sputnik V (Gamaleya National
Research Institute of Epidemiology and Microbiology) is a non-replicating heterologous
recombinant adenovirus (rAd)-based vaccine that combines a recombinant adenovirus type
26 (rAd26) for the first dose and a recombinant adenovirus type 5 (rAd5) for the second
dose, both carrying the sequence that encodes the spike protein (S) of the SARS-CoV-2.
Ad5-nCoV (CanSino Biologics, Tianjin, China) is a non-replicating viral vector vaccine
based on a recombinant adenovirus type 5 (Ad5) that contains the sequence that encodes
the spike protein (S) of the SARS-CoV-2. On the contrary, viral vector vaccines represent the
most common engineered veterinary vaccine type. Several poxviruses, including fowlpox
and canarypox, have been used for the development of several licensed vaccines for veteri-
nary diseases, such as Newcastle disease, avian influenza, equine influenza, rabies, FeLV
and canine distemper [60,61]. A comprehensive analysis of the status of poxvirus vaccines
under development for veterinary and human use is described by Sánchez-Sampedro and
colleagues [62]. Another variant of the vectored vaccine approach is use of a live-attenuated
viral pathogen as vector to induce protection against two diseases at once.
3.3. Nucleic Acid–Based Vaccines
Nucleic acid vaccines are based on DNA cloned into a delivery plasmid or the direct
injection of messenger RNA (mRNA) to express antigens into the host cells [38]. The
endogenous protein synthesis mimics a natural infection eliciting both cellular and humoral
responses [38]. The synthetic nature of this method also results in a high safety profile and
a rapid manufacturing ability [63]. In addition, circumventing the need of cell cultures for
protein expression results in lower manufacturing costs. Nevertheless, although mRNA
vaccines are produced by in vitro synthesis through enzymatic processes, they rely on DNA
as starting material. Plasmid DNA are typically amplified in E. coli and purification steps
are also required. The recent production of COVID-19 vaccines has increased the demand
of DNA production and current processed may become a bottleneck. The DNA industry is
looking toward innovations in cell-free processes to meet the growing demand. Companies
such as DNA Script (Paris, France) and Touchlight (Hampton, UK) are developing their
own technologies to achieve this goal. In contrast to mRNA, DNA has an increased stability,
avoiding the need of frozen storage and low temperature transportation. Nevertheless,
this method generally requires further delivery formulations or specific delivery devices to
reach good immunogenicity [64]. Promising results achieved in animal models with DNA
vaccines were hardly reproduced in clinical studies, showing lower immunogenicity [65,66].
These results in bigger animals and humans are probably due to the difficulty to upscale the
DNA vaccine amounts used in small animals [67], leading to lower amounts of expressed
antigens. To get inside the cells, DNA molecules require a physical delivery method,
commonly based on electroporation technology and DNA molecules that successfully enter
the cell and also need to cross the barrier of the nuclear membrane to be transcribed [68],
decreasing the amount of effective DNA molecules. Therefore, improvements in delivery
methods are key to increase the amount of DNA that finally is transcribed in the nucleus
to generate an appropriate amount of antigen to prompt an effective immune response.
Although the potential of DNA vaccines to integrate into the host cell genome was one of
the primary safety concerns [69], multiple studies have confirmed that the rate of genomic
integration is negligible, demonstrating that they have an extremely low probability of
Biomolecules 2021, 11, 1072 7 of 33
genome integration [70]. Furthermore, the manufacturing process for DNA plasmid
vaccines is well-established, and DNA vaccines have already been approved for veterinary
purposes. Some examples are Apex-IHN® (Novartis Aqua Health, Basel, Switzerland),
which protects Atlantic salmon from infectious hematopoietic necrosis (IHN); West Nile–
Innovator® (Zoetis, Parsippany, NJ, USA), an equine vaccine that protects from West
Nile virus (WNV); and ONCEPT® (Boehringer Ingelheim, Ingelheim, Germany), a cancer
vaccine that is used to treat canine malignant melanoma (CMM) [12].
Regarding human vaccines, mRNA vaccines have emerged as a promising vaccina-
tion strategy to face pandemic infectious diseases such as the recent COVID-19 disease.
This platform led to a rapid vaccine development, and two novel mRNA vaccines were
approved: Comirnaty® (Pfizer, New York, USA and BioNTech, Mainz, Germany) and
COVID-19 Vaccine Moderna (Moderna, Cambridge, MA, USA), both of them nucleoside-
modified messenger RNA produced by using a cell-free in vitro transcription from the
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2.
RNA vaccines possess important advantages, including efficacy, safety and the poten-
tial for rapid, inexpensive and scalable production [71]. They lack the risk of insertional
mutagenesis because they are based on the delivery of mRNA molecules directly into the
cytoplasm of host cells, where antigens are transcribed, without the need to be directed to
the cellular nucleus [40]. However, mRNA require a delivery system that not only protects
the nucleic acid from degradation but also assists their entry into the cells. These molecules
are large to diffuse into cells and their dense negative charge electrostatically repulses the
anionic cell membrane, avoiding their uptake [72]. Recent COVID-19 mRNA vaccines
are based on the use of lipid nanoparticles (LNPs) made of ionizable lipids as delivery
vehicles [73]. Ionizable amine groups are positively charged at low pH, interacting with
the anionic mRNA during particle formation and also facilitating membrane fusion during
internalization [74,75]. A key aspect of LNPs that makes them different from liposomes is
the presence of lipids in the core; however, data from several studies indicate that water is
also present to some extent [76–78]. Moreover, mRNA-LNPs are endocited by cells and
mRNA molecules are released into the cytoplasm. Lipid nanoparticles usually contain
a helper lipid to promote cell binding, cholesterol to fill the gaps between the lipids and
a polyethylene glycol (PEG) to reduce opsonization by serum proteins and reticuloen-
dothelial clearance [72,79]; however, the final formulation needs to be optimized for each
purpose.
Several strategies have been developed to solve the common issues of mRNA vaccines
related to in vivo stability, translation capacity and reactogenicity of mRNA. Stability and
translational efficiency can be improved by the optimization of the regulatory regions
of mRNA: 5′ cap, poly-A tail and untranslated regions (UTRs) [73]. Furthermore, maxi-
mization of GC (guanine–cytosine) content in combination with codon optimization by
selection of frequent codons in the coding region also allows to enhanced stability and
translation [80,81]. The secondary structure of mRNA is also of great importance and it
can be stabilized by changing the primary sequence through codon optimizations and
bioinformatics prediction. Alternatively, it has been reported that the incorporation of
naturally occurring modified uridines, such as the use of 1-methyl-pseudouridine (m1Ψ)
instead of uridine, induces global changes in the secondary structure of mRNA which
correlates with high protein expression [82]. Furthermore, modification of uridines is also
an efficient way to minimize reactogenicity of mRNA, decreasing the cellular recognition
by RNA-binding proteins involved in the innate immune response to foreign mRNA [73].
3.4. Protein-Based Vaccines
Protein vaccines use peptides or proteins as antigens to induce an immune response.
As previously described, protein antigens can be obtained from the pathogen that causes
the infectious disease as a natural source, either in their whole form or as derived split-
products. Although protein vaccines produced from natural infectious agents still fulfill an
important role, they show some disadvantages, as production and purification processes
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are costly, time-consuming and require the growth of large quantity of pathogens [38]. In
addition, some viruses cannot be cultivated efficiently or are risky to cultivate in large
scale, making difficult the production from natural sources. In other cases, human proteins,
such as certain protein factors, could also be required for treatment of non-infectious
diseases, such as hypertension and cancer [83]. As an alternative to natural sources, protein
subunit vaccines can also be produced as heterologous proteins in recombinant systems.
Production through well-established expression systems, including recombinant bacteria,
yeast, insect cells or mammalian cells, is considered to be more cost-effective [83] and
safe compared with natural sources. Nevertheless, the process to find the appropriate
antigenic component to produce an effective immune response is time-consuming [8,84].
Although full-length proteins can induce the development of antibodies against multiple
epitopes and they tend to maintain their native conformation [39], they also increase the
possibilities of inducing nonspecific cross-reactive antibodies [85]. Since only specific
amino acid sequences of the full-length antigen are responsible for effective immune
responses, selected immunogenic peptides mimicking B- and T-cell epitopes have also been
proposed as vaccine candidates [85]. Consequently, optimizing amino acid sequence is of
great importance to promote epitopes associated with neutralizing antibodies, that block
pathogens and confer protection, while reducing epitopes associated with non-neutralizing
antibodies [86]. Subunit vaccines tend to generate low immunogenicity in comparison
with traditional vaccines due to relative small sizes and low valences of the antigens or
epitopes [83]. Moreover, whole-organism vaccines, whether inactivated, attenuated or
from a closely related species, do not expose just one copy of an antigen, because they
contain multiple copies of each antigen, as well as other immunostimulatory molecules, and
with subunit protein vaccines, this effect does not occur [8]. Many approaches have been
explored to develop effective subunit vaccines, including the use of adjuvants to stimulate
the immune system and the use of nanotechnology to generate effective antigen display
systems [87]. The addition of adjuvants can help the vaccine to be more immunogenic,
induce a stronger humoral or cellular immune response, increase antigen processing
by APC, decrease the total amount of vaccine that needs to be injected or aid in the
development of a long term memory response [88]. Marketed protein-based vaccines for
human and veterinary use, classified by production system, are listed in Tables 1 and 2,
respectively.
Table 1. Recombinant protein vaccines approved for human use.
Production





Bacteria E. coli HEV Hecolin® (Innovax) 2012 * ORF2 HEV VLP [89,90]
Yeast
S. cerevisiae HBV Recombivax HB
®
(Merck & Co.)
1986 FDA HBsAg VLP [91,92]
S. cerevisiae HBV Engerix®-B (GSK) 1989 FDA HBsAg VLP [93,94]
S. cerevisiae HBV HBvaxPRO
®
(Merck & Co.)
2001 EMA HBsAg VLP [95]






2021 EMA HBsAg VLP [97,98]






HPV 6, 11, 16, 18 VLP [99–101]






HPV 6, 11, 16, 18,
31, 33, 45, 52, 58
VLP [102,103]
S. cerevisiae Malaria Mosquirix® (GSK)
2015 EMA
(outside EU) RTS,S VLP [104–106]
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Table 1. Cont.
Production





























2018 EMA gE Subunit [113–115]
* Granted a marketing authorization in China by China Food and Drug Administration. Phase 1 clinical trial approved by FDA
(NCT03827395). HEV: Hepatitis E virus; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; VLP, virus-like particle; HPV,
human papillomavirus; RTS,S, P. falciparum protein fused with hepatitis B surface antigen (RTS) combined with hepatitis B surface antigen
(S); HA, hemagglutinin; CHO, Chinese hamster ovary cell; gE, herpes zoster virus glycoprotein E.










E. coli FeLV Leucogen
®
(Virbac)




2016 EMA L. infantum MON-1Q protein Subunit [118]
Insect cells
Sf21 CSF Porcilis Pesti
®
(Merck & Co.)
2000 EMA E2 glycoprotein Subunit [119,120]
Sf21 CSF Bayovac
® CSF E2 *
(Bayer)

























2019 EMA PPV 27a VP2 VLP [128]
* Bayovac® CSF E2 vaccine has been discontinued. FeLV, feline leukemia virus; CSF, classical swine fever; PCV2, porcine circovirus type
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production (n.s.).
4. Nanotechnology Applied to Subunit Vaccines
An emergent area in the development of vaccines is the use of nanotechnology that
works with a wide range of materials to generate effective antigen display systems. These
non-replicative and organized structures on a nanoscale of 1–100 nm can be produced by
recombinant expression [129] or chemical synthesis [130]. While biological nanoparticles
have thus far predominated nanovaccine trials, inorganic and chemically synthesized
nanoparticles, including metals [131] and synthetic polymers [132], are also being explored
in preclinical studies. Some of the biological approaches to generate effective antigen
display systems are the use of VLPs and subviral particles, ferritin cages, vault particles,
encapsulins, liposomes, virosomes and outer membrane vesicles, among others [8].
4.1. VLPs and Small Subviral Particles
Virus-like particles (VLPs) mimic the natural process of viral capsid self-assembling
through recombinant technology to generate particles that exhibit similar structural and
antigenic properties of their authentic viruses [83]. Small subviral particles can also be
constructed by generating truncated viral structural proteins [12]. They resemble the size
Biomolecules 2021, 11, 1072 10 of 33
and shape of viruses but do not contain any viral genetic material, meaning that they are
not infectious [50]. VLPs offer the advantage of being repetitive antigen display systems
and it has been demonstrated that antibody titers increase when antigens are displayed
repetitively [50,133] due to an increase of crosslinking B-cell receptors leading to B-cell
activation [15,134,135]. In addition, VLPs possess self-adjuvanting properties due to their
particulate structure and optimal size for uptake by antigen presenting cells [136,137]. Thus,
they are efficiently processed by APCs, leading to activation of T cells, making them an
interesting tool for increasing the immunogenicity of antigens [50]. VLPs can be antigens
themselves, meaning the protein that assembles into the VLP is the antigen of interest. This
is the case for VLP vaccines such as HBV, HPV, PCV2 or PPV. Alternatively, VLP can be used
as a scaffold or carrier for the delivery of heterologous antigens as a platform technology.
Well-reported platforms based on self-assembling proteins acting like carriers include HPV
L1 [138] and hepatitis B core [139] or surface antigens [140,141], among others. VLPs are
usually produced in bacteria, yeast or insect cells as expression system [142]. Expression of
large genetically fused antigens is challenging, and strategies such as linker designs [143],
antigen titration [106,143,144], split-intein conjugation [145–147] and tandem core fusion
strategy [148] are implemented to enable ease of large antigen modularization. The vaccine
RTS,S/AS01 Mosquirix® (GSK, Londres, UK) against malaria [104,106] is one of such
combination vaccines that has reached the market. It consists of hepatitis B surface antigen
(S) VLPs containing a portion of Plasmodium falciparum–derived circumsporozoite protein
(RST). Further VLP vaccines have been approved for human use, such as Recombivax
HB® (Merck & Co., Kenilworth, NJ, USA) and Engerix®-B (GSK, Londres, UK) against
hepatitis B virus (HBV), Gardasil® (Merck & Co., Kenilworth, NJ, USA) and Cervarix®
(GSK, Londres, UK) against human papillomavirus (HPV) and Hecolin® (Innovax, Xiamen,
China) against hepatitis E virus (HEV).
4.2. Ferritin Cages
Ferritin cages are protein assemblies derived from ferritin, an iron metabolism protein
present in bacteria, animals and plants that, under normal conditions, self-assemble into a
spherical particle of 24 monomers with octahedral symmetry containing an open central
cavity [149]. The overall diameter of the particles is 12 nm and the cores have a diameter
of 8 nm [150]. Although ferritin cages seem excellent candidates for repetitive display
antigens, the main limitation is their rigid assembly. Thus, if an antigen needs to be
presented in a certain conformation to be immunogenic, ferritin cages may not be able to
present it in the most immunogenic form [8].
4.3. Vault Particles
Vaults are naturally occurring nanoparticles found widely in eukaryotes as a 70 nm
organelle-like structure that is composed of the major vault protein (MVP), telomerase
associated protein-1, poly ADP-ribose polymerase (PARP) and non-coding RNAs [151].
They are not immunogenic and do not lead to the development of autoimmune responses
making them a good vaccine delivery system [152]. Nevertheless, their biggest weakness is
that antigens, instead of being exposed at the surface of particles, are contained within the
vault cavity, lacking the direct stimulation of B cells responsible for humoral responses [8].
4.4. Encapsulins
Recently, a new class of prokaryotic compartments, known as encapsulins or protein
nanocompartments, has attracted the attention in the field of nanotechnology as systems
for delivery being of great interest as potential antigen display systems. Encapsulin protein
self-assemblies to form an icosahedron made of 60 identical subunits, with a diameter of
25–42 nm, differing in size depending on the bacterial source [153]. Foreign antigens can
be either encapsulated in the nanocompartment as cargo or exposed at the surface of the
nanoparticles. A recent work demonstrated that when Epstein–Barr Virus glycoprotein
350/220 (gp350) was expressed at the surface of encapsulins, potent neutralizing antibodies
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were elicited in mice and non-human primates, increasing neutralization 10- to 100-fold
compared to soluble gp350 [154].
4.5. In Silico Designed Nanoparticles
An alternative to naturally occurring nanoscale assemblies are in silico rationally
designed particles, able to self-assemble into nanoscale assemblies to improve antigen
display. Examples of successfully designed two-component nanoparticles as vaccine
candidates include BG505 SOSIP-I53-50 nanoparticles for HIV [155], DS-Cav1-I53-50A
nanoparticles for Respiratory Syncytial Virus (RSV) [156] and BG505 SOSIP–T33_dn2
nanoparticles for influenza, HIV and RSV [157].
5. Traditional Platforms for Protein Vaccine Manufacturing
Bacteria (E. coli), yeast, insect cells and mammalian cells have been used traditionally
as platforms for production of recombinant proteins. Regarding vaccine manufacturing,
according to the number of approved recombinant protein vaccines for human use (Table 1),
yeast and insect cells are the most extensively used production platforms for this industry.
Furthermore, they are also the preferred platforms for VLP manufacturing purposes. In
the case of animal health, insect cells are the dominant platform for recombinant vaccine
manufacturing (Table 2).
5.1. Bacteria (E. coli)
The first recombinant expression system was established using E. coli bacteria, the
microbe used to develop the early concepts of molecular biology [38]. This expression
system is characterized by high protein yield, fast growth rate, high productivity, short
production times and low manufacturing cost. The price of culture medium and upstream
processing for this platform is significantly lower when compared to eukaryotic systems
such as insect or mammalian cell cultures. However, this system also has some disadvan-
tages such as the lack of eukaryotic post-translational modifications that can lead to the
expression of misfolded, insoluble or nonfunctional proteins. Complex antigens requir-
ing post-translational modifications (e.g., glycosylation and multimer assembly) cannot
be correctly produced in this platform [27]. Engineered bacteria able to induce specific
post-translational modifications can solve this problem, but it makes the process more diffi-
cult [158]. Furthermore, the removal of contaminant endotoxins generated in this system,
mainly lipopolysaccharide, should also be taken into account in the manufacturing process.
Despite active investigation of novel systems, E. coli remains the dominant bacterial strain
in use [159] because is easy to engineer and adapt to new constraints, such as antibiotic-free
selection [160,161]. Furthermore, development of new bioinformatic tools has enabled
prediction of potential expression issues, as could be protein solubility upon overexpres-
sion [162]. Regarding human health, the first vaccine produced in E. coli was approved in
2012 for market commercialization in China. Hecolin® (Innovax, Xiamen, China) is the first
world vaccine against Hepatitis E virus and is based on the ORF2 capsid protein of HEV
that is refolded after expression and self-assembly into VLP [89,90]. Recently, the FDA has
approved Hecolin® to enter a Phase 1 clinical trial in the United States (NCT03827395).
A recombinant HPV type 16/18 bivalent vaccine produced in E. coli (Cecolin®; Innovax,
Xiamen, China) has also been approved recently for marketing in China. In addition, a
recent study has shown that Plasmodium vivax antigens expressed in E. coli induced humoral
and cellular immune responses in mice, showing promising results as potentially useful
vaccine candidates against P. vivax malaria [163]. One of the first recombinant veterinary
vaccines to be successfully produced in E. coli was Leucogen® (Virbac, Carros, France), a
purified recombinant p45 FeLV-envelope antigen that was derived from the gp70 surface
glycoprotein of the FeLV [116,117]. Another example is Letifend® (LETI Pharma, Barcelona,
Spain), a recombinant vaccine against Canine leishmaniasis based on a recombinant protein
Q from Leishmania infantum also expressed in E. coli [118].
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5.2. Yeast
Yeasts are attractive hosts for recombinant protein expression due to their fast growth,
high protein yield, simple handling, low production costs and industrial production knowl-
edge, advantages that have in common with prokaryote systems. Moreover, they also
possess some advantages of eukaryotes systems such as the capacity to perform post-
translational modification of proteins in a manner similar to that used by higher eukaryotic
cells, allowing recombinant proteins to be more likely correctly folded [38]. All these advan-
tages make yeast a cost-effective production system when compared to higher eukaryotic
systems such as animal cells. Regarding safety, they also avoid the endotoxin problem
that is associated with bacterial expression systems and viral contamination of mammalian
expression systems [164]. Yeasts also face some challenges, as their glycosylation pattern is
distinct from that carried out by mammalian cells, leading to hyperglycosylation (excess of
mannose residues) of recombinant proteins. To change the high-mannose profile of yeast to
the human-type complex glycan pattern, the glycosylation pathways have been genetically
altered in some strains, such as S. cerevisiae [165,166], H. polymorpha and Pichia pastoris
(P. pastoris) [167,168]. Moreover, yeasts are also being engineered to overexpress chaper-
ones with the aim to enhance secretion and folding of recombinant proteins [169–171]. S.
cerevisiae is the most extensively used yeast host for heterologous protein production and
several vaccines have already been successfully produced in this system. Recombivax HB®
(Merck & Co.) was the first recombinant vaccine approved for human use and is directed
for treatment of hepatitis B, based on HBV surface antigen (HBsAg) that self-assembles
into VLPs [91,92]. HBsAg was previously produced in E. coli but it was not immunogenic,
which led to a search for a different expression host [172–174]. The second example is
a vaccine directed against HPV and is based on the structural L1 protein that also self-
assembles into VLPs (Gardasil®, Merck & Co.) [99–101]. Although many heterologous
proteins have been successfully expressed in S. cerevisiae, this system also faces some issues
related with low yields of protein expression and hyperglycosylation, which may result
in differences in immunogenicity, diminished activity or decreased serum retention of the
foreign protein [175]. Non-conventional strains such as P. pastoris are being explored as
alternative hosts to surmount the abovementioned limitations.
5.3. Insect Cells
Insect cells have been widely used for recombinant protein expression because of their
capacity to produce high levels of proteins and to perform post-translational modifications,
including glycosylation, phosphorylation, disulfide bond formation and protein processing
required for the biological activity of many complex proteins [176]. Although stable
transformed insect cell lines can be generated, the most extended system is the transient
expression driven by recombinant baculovirus infection. Baculovirus expression vector
system (BEVS) is one of the most well-known and used systems for large-scale production of
complex proteins. Baculoviruses are insect pathogens and do not represent a human health
risk. They can be easily modified to incorporate multiple additional foreign genes, and
Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is one of the dominant
vectors. The protein of interest is usually produced under the control of the polyhedrin
(polh) promoter, one of the strongest promoters known in nature [177], which can express
foreign proteins up to 50% of total cell proteins [38]. The p10 promoter that is active at
an earlier time post-infection is also widely used; however, in general, it reaches lower
levels than the polh promoter [178]. The use of multiple promoters makes possible the
expression of several proteins simultaneously in a single infection. The most commonly
used lepidopteran insect cell lines are Sf21 and Sf9 derived from Spodoptera frugiperda
and the BTI-TN-5B1-4 cell line (High Five™) derived from Trichoplusia ni [159]. These
cells grow in suspension without requirement of CO2 leading to a feasible scale up of
protein production. Insect cells are less demanding and grow to higher densities than
mammalian cell lines, but they also demand expensive culture medium and the use of
bioreactors, which increases the production costs. Expression levels as high as 1 g per liter
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could be obtained; however, levels can vary considerably from 1 to 600 mg depending
on the antigen [38]. On the other hand, insect cells have also some limitations as they
cannot synthesize mammalian-specific complex glycan structures. N-glycans from insect
cells are not processed to terminally sialylated complex-type structures but are instead
modified to paucimannose structure [179]. This issue has been addressed by genetic
modification of either insect cells [180–183] or baculoviruses [184] to include genes encoding
N-glycosylation functions. In addition, although the growth rate of insect cells is higher
than mammalian cells, it is still lower when compared to yeast or bacteria, and production
requires more expensive culture media and longer times than those required for microbial
systems.
Recently, vaccines produced in insect cells have been commercialized, demonstrating
that this form of production has potential as a commercial manufacturing technology [185].
The first commercially available veterinary vaccines produced in insect cells were classical
swine fever virus (CSFV) vaccines (Bayovac® CSF E2; Bayer, Leverkusen, Germany and
Porcilis Pesti®, Merck & Co., Kenilworth, NJ, USA), based on the E2 antigen [119–121]. In
addition, veterinary vaccines against PCV2 based on the ORF2 protein were also approved:
IngelVac CircoFLEX® (Boehringer Ingelheim, Ingelheim, Germany) [122–124], Porcilis®
PCV (Merck & Co.) [126], Circumvent® PCV2 (Merck & Co.) [125] and CircoGard® (Phar-
mgate, Wilmington, NC, USA) [127]. A vaccine against porcine parvovirus, ReproCyc®
ParvoFLEX (Boehringer Ingelheim, Ingelheim, Germany), based on the viral protein 2
(VP2) was also approved for commercial use in 2019 by the EMA [128]. The first hu-
man vaccine produced in insect cells, Cervarix® (GSK), was licensed by the European
Medicines Agency (EMA) in 2007 and by US Food and Drug Administration (FDA) in
2009 [108,109]. Cervarix® is a bivalent human papilloma virus vaccine (HPV 16 and 18)
based on the expression in High Five™ cells of the major capsid protein L1 of HPV that
self-assembles to form VLPs [107]. The second product for human use licensed by the FDA
was Provenge (Dendreon, Seal Beach, CA, USA) [186,187], an autologous prostate-cancer
therapy. The antigen PA2024, a fusion protein of prostatic acid phosphatase (PAP) and
granulocyte–macrophage colony-stimulating factor (GM–CSF) produced in Sf21 cells is
used to stimulate dendritic cells from each patient ex vivo that will be further used as a
cellular vaccine. Moreover, recombinant influenza vaccines based on the hemagglutinin
(HA) surface antigen produced in insect cells developed by Protein Sciences (now owned
by Sanofi Pasteur, Lyon, France) have also been approved: Flublok® [110,111] and Flublok
Quadrivalent® (Supemtek® in EU market) [112].
Alternative insect cell line as Drosophila Schneider line 2 (S2 cells) is also being used as
a stable, nonviral and nonlytic expression system able to successfully produce difficult to
express proteins [159]. They are also suitable for cultivation, using batch, fed-batch and
continuous cultivation techniques [159]. This system is being explored for the development
of vaccine candidates against dengue virus [188] by Merck & Co., West Nile virus [188]
by Hawaii Biotech (Honolulu, HI, USA) and also two malaria vaccines from the Jenner
Institute (University of Oxford) and Copenhagen University, respectively [188].
5.4. Mammalian Cells
Mammalian cells are extensively used to manufacture diverse immuno- and biother-
apeutic molecules, due to their high and robust productivity and secretion of complex
molecules in serum-free medium and their ability to perform complex post-transcriptional
modifications [189], such as precise glycosylation. Some of the limitations of this system
are that the speed of production is low, the cost is high (culture media and fermentation sys-
tem) and there is also a potential risk for endogenous virus contamination [159]. To avoid
virus contamination, biopharmaceutical manufacturing processes follow measures based
on prevention, in-process control and clearance according to regulatory guidance [190].
Prevention of virus entry is achieved by selecting low-risk starting and raw materials and
performing manufacturing controls. In-process testing of materials validate the absence of
viruses, assuring lot rejection in case of contamination. Finally, a step of virus clearance for
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virus inactivation and/or removal is performed to assure the absence of viral contamination
in the final product.
More than 60% of the currently available immunotherapeutic molecules produced
in mammalian cells are monoclonal antibodies [159]. Regarding vaccine manufacturing,
mammalian continuous cell lines (CCLs) are used for virus propagation in the production
of virus-based vaccines. Vero (African monkey kidney epithelial) cell line is one of the
most widely used for this purpose and has been used for production of polio and rabies
virus vaccines [191]. The use of mammalian cells for the production of recombinant protein
vaccines is also possible, but costs of manufacture are high and expression levels can be
lower than those achieved by using alternative expression systems. Nevertheless, this
system could be useful for the expression of complex vaccine candidates.
Two of the most commonly used mammalian cell lines for recombinant protein expres-
sion are Chinese Hamster Ovary (CHO) and Human Embryonic Kidney 293 (HEK293) cells.
The CHO cell line was derived from a biopsy of the ovary of the Chinese hamster while
the HEK293 cell line was generated by transfection of a human primary embryonic kidney
cell culture with sheared DNA of adenovirus type 5 (Ad5). Both cell lines can be grown in
suspension or as adherent cultures; however, suspension cultures are the preferred choice
at the industrial scale, as they are easier to scale up and to adapt to automated processes.
Expression of foreign genes can be achieved either by transient or stable expression. For
large amounts of protein production, stable cells are preferred, as they provide high yields
with consistent quality. Taking into account that the generation of stable cell lines is time-
consuming, transient expression that results in high levels in short periods is usually the
method of choice for rapid protein production during Proof-of-Concept stages. HEK-293
cells are often used for transient expression due to its high transfection efficiency while
CHO cells are more commonly used for stable cell line expression. HEK-293 cells show
different glycosylation patterns from those proteins made in CHO cells, a feature to be
considered during development if the host cell type required to be modified, as it could
affect the biologic activity of the proteins expressed.
Development of recombinant cell lines for stable protein expression relies on the
integration of a plasmid containing the sequence of interest into the genome. When cells
are transfected by chemical reagents or by electroporation, non-homologous recombination
occurs in a small portion of the cell; however, the efficiency of this process is very low. To
achieve a stable expression, it is necessary to integrate the genes of interest at sites of the
genome that are transcriptionally active, that do not experience gene silencing [192] and
that are not susceptible to genetic rearrangement [193]. Viral vectors can be used as tools
for this purpose, as they target transcriptionally active regions of the genome to integrate
their DNA. Lentiviral vectors can transduce CHO cells with high vector copy and remain
stable for many months [194,195]. Alternative systems are non-viral adeno-associated virus
(AAV) system, based on the AAV machinery [193] or the novel viral vector system Semliki
Forest virus (SFV), developed from alphaviruses [196].
As the genome sequence of several production cell lines is already available, editing
of genomic sequences with nucleases is also possible. The CRISPR/Cas system has been
successfully used for genome editing in CHO during cell-line development [197], and
site-specific integration of a therapeutic gene has also been reported [198].
CHO cells are widely used for production of recombinant glycoprotein therapeutics
due to their high productivity (1–10 g per liter), genetic stability and ability to grow in
large-scale suspension culture [199–201] in serum-free medium. However, many recom-
binant proteins, including monoclonal antibodies, antibody fusion proteins and IFN-γ,
are partially degraded or proteolyzed by endogenous CHO cell proteases during the cell
culture or recovery process [202–207]. Novel approaches to solve proteolysis and enhance
glycosylation for production of HIV envelope proteins as vaccine candidates are being
explored [208]. The HEK293 cell line is also a platform of interest for production of re-
combinant viral vectors and vaccines at the industrial scale, because the cells are easy to
grow in suspension and can be adapted to serum-free medium. Current developments
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of human vaccines using HEK293 cells include the expression of glycoproteins for the
treatment of infectious diseases, such as rabies [209] or Ebola virus [210]. A recent study of
a vaccine candidate against Trypanosoma vivax showed that an invariant antigen expressed
in HEK293 cells was able to induce protective immunity in mice [211], showing promising
results as a vaccine candidate. A Zika virus vaccine candidate expressed in HEK293T cells
(a HEK293 cell line derivative transfected with a SV40 expression construct) was reported
to protect against ZIKV challenge in pregnant mice [212].
Although the application of mammalian cells to vaccines development is still limited,
already there is a human vaccine produced with CHO cells that is approved for human
use. Shingrix (GSK, Londres, UK) is a herpes zoster vaccine based on varicella zoster virus
glycoprotein E (gE) [113–115].
6. Alternative Platforms for Protein Vaccine Manufacturing
Traditional vaccine platforms meet market demands for some application but costs
of manufacturing, scale capability and times required for development make difficult
to accomplish other market requirements. Conventional vaccine-manufacturing tech-
nologies are limited to producing only one vaccine or a very narrow range of vaccines;
thus, individual manufacturing processes need to be developed for each vaccine, making
vaccine-manufacturing-process development costly and time-consuming [213]. It is esti-
mated that developing a vaccine from concept to market costs $200 million–$500 million
and takes 5–18 years [214–218]. Additionally, it costs an estimated $50 million–$700 million
to construct, equip and commission a vaccine manufacturing facility, taking on average
7 years [215,216,219,220], while the manufacture process of a vaccine ranges between
0.5 and 3 years [215,221]. Platform technologies allow the standardization of upstream
and downstream processes, given that the platform base remains unchanged. Certain
processes would require optimization but this system provide flexibility and possibility
for multi-product facilities [44]. Flexible, rapid and low-cost vaccine development and
manufacturing technologies are required to meet vaccination demands in low- and middle-
income countries and to face possible future epidemics. Tight profit margins associated
with intensive animal production also reveal the necessity to produce inexpensive vac-
cines for animals [12]. The lower cost for veterinary vaccination in the range of cents
per dose [222] compared with a typical cost range of $20–$130 per dose for recombinant
human vaccines (http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm,
accessed on 1 June 2021), evidences that low-cost vaccine development and manufacturing
technologies are critical for animal health. Therefore, there is a pressing need of alternative
production platforms that can overcome all the existing limitation in vaccine production.
Within the development of alternative systems, two main strategies can be considered: the
rational engineering of existing systems and the development of completely alternative
hosts. The engineering approach may be useful to improve the quality of the expressed
protein such as the glycosylation profile, but in terms of productivity the improvements
will meet limits due to the physiological capacity of the systems. In this case, the use of new
hosts with a naturally extended capacity for very high protein production and secretion
could offer higher potential [159].
6.1. Non–E. coli Bacterial Systems
Some alternative Gram-negative hosts have been explored as expression systems, but
their utility still remains marginal in comparison with E. coli. One of them is Pseudomonas
fluorescens [223], for which a complete toolbox for protein expression and strain selection
is available. Another host that is considered outstanding for its high metabolite output is
Ralstonia eutropha [224]; however, tools for protein expression in this system are still limited.
Regarding Gram-positive hosts, many Lactic Acid Bacteria (LAB), such as Lactobacillus
and Bifidobacterium, have been extensively used in the food industry as probiotics. They
represent an attractive tool for oral vaccine production and delivery because of their GRAS
status, reported adjuvant properties, mucoadhesive ability, easy genetic manipulation
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and the availability of well-defined industrial production processes [225,226]. Effective
mucosal immunogenicity and protection after oral and nasal vaccination have been re-
ported using Lactobacillus strains expressing antigens against several viral and bacterial
pathogens [227–232]. Nevertheless, vaccine strains cannot be considered avirulent, even
if they could be listed as GRAS, due to potential transfer of antibiotic selection markers
among microbes [233,234]. To solve this issue, a carrier system called Gram-positive en-
hancer matrix (GEM) based on non-recombinant Lactococcus lactis bacteria was recently
developed. It is composed of the rigid peptidoglycan (PGN) cell wall resulting in a non-
living particle that preserves the shape and the size as the original bacterium [235]. GEMs
can be used both mixed with vaccine antigens as adjuvants or as antigen protein carriers
with the antigens bounded to their surface [34].
6.2. New Approaches in Yeast Platform
In addition to S. cerevisiae other non-conventional strains are also of great interest
for production of therapeutic proteins such as Pichia pastoris (P. pastoris), Saccharomyces
boulardii (S. boulardii) and Kluyveromyces lactis (K. lactis) [236]. A comparative of advan-
tages and disadvantages of different yeast species as hosts for expression of heterologous
proteins has been extensively discussed by Vieira Gomes and colleagues [237]. P. pastoris
is one of the most studied non-conventional strains for the production of recombinant
protein antigens for human vaccines [238,239] because is capable of performing human-
like post-translational modifications, showing weaker hyper-mannosylation than those
performed by S. cerevisiae [164]. Expression in P. pastoris also offers advantages for secreted
recombinant proteins as it grows on a simple mineral media and secretes only low levels of
endogenous proteins. Therefore, the heterologous protein can comprise the major portion
of the total protein in the medium, leading to an easier purification process [240]. Antigens
from virus, protozoa, bacteria, nematode and tick expressed in different species of yeast,
including P. pastoris, have been extensively reviewed by Kumar and colleagues [241]. Re-
cently, it has been reported that Zika virus envelope protein (80E) expressed in P. pastoris
is able to elicit potent ZIKV-neutralizing antibodies in mice conferring significant protec-
tion in vivo [242]. SARS-CoV-2 recombinant receptor-binding domain candidate vaccine
expressed in P. pastoris has also been reported to be able to stimulate virus neutralizing
antibodies and T-cell immunity in mice [242].
New approaches in recombinant yeast vaccine technology include the use of inac-
tivated whole yeast cells [243] or antigen display at the yeast cell surface [242] as vac-
cination strategy. These technologies are of great interest for the development of oral
vaccines at low-cost because no purification is needed. In addition, they could serve
as a universal technology platform for vaccine development. The GRAS status of some
strains, such as S. cerevisiae, and the properties of the cellular wall to protect the anti-
gens across the gastrointestinal tract make engineered yeast an attractive vaccine delivery
system [27,244]. Moreover, this delivery system could also enhance immunogenicity of
vaccines due to the adjuvant activity of β-glucans on the yeast cell wall that have demon-
strated immunomodulatory and adjuvant effects through the binding of innate pathogen
receptors on macrophages, DC and neutrophils [245]. Some preclinical studies based on
orally administrated S. cerevisiae displaying antigens on its surface for different infectious
agents, such as influenza, showed that this delivery system is able to induce both humoral
and cellular responses in mice [242]. Current developments include the expression of the
spike protein of SARS-CoV-2 on the surface of S. cerevisiae as vaccine candidate, showing
promising results in mice [246].
6.3. Transgenic Animals
Complex proteins can be produced by generating transgenic animals not only in
mammalian species such as goat, sheep, rabbit or pig capable of expressing proteins in
milk, but also in transgenic hens [247,248] or even ostriches [249] that can produce proteins
in egg albumen. The selection criteria for the transgenic animal is of primary importance
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and includes parameters to be considered such as annual dairy production, reproductive
performance or age of sexual maturity [250]. Safety issues, such as cross-contamination
should also be considered, and animals should be able to be maintained in pathogen-free
conditions to prevent contamination [251]. Moreover, the ongoing ethical and societal
debate around the use of transgenic animals includes concerns related to animal welfare and
the use of genetically modified organisms (GMOs) [252,253]. Furthermore, the investment
required to develop an innovative platform that still poses a high degree of uncertainty, so,
at present, the big companies prefer to improve the use of mammalian cells rather than
explore transgenic animals [254].
Despite the relative complexity and lengthy timelines associated with the generation
of transgenic animal bioreactors, there are some niche therapeutic areas where this system
could be useful, including high-added-value markets requiring complex molecules for
which other systems have failed or cannot fulfill demand [159]. The first recombinant
protein approved for human use expressed in transgenic animals was a human antithrom-
bin III (ATryn®; rEVO Biologics, Framingham, MA, USA) produced in goat milk. It was
approved by the EMA in 2006 and by the FDA in 2009 for treatment of patients with
hereditary AT deficiency [255]. This case reveals the potential of transgenic animals since
a single genetically modified goat can produce as much antithrombin in a year as 90,000
blood donations [256]. In 2011 the EMA approved an additional biologic (Ruconest®;
Pharming, Leiden, the Netherlands), a recombinant C1-esterase inhibitor for the treatment
of hereditary angioedema produced in the milk of transgenic rabbits. Eggs from transgenic
chickens are also a promising system for recombinant protein production. In 2015, the FDA
and EMA approved Sebelipase alfa (Kanuma®; Alexion, Boston, MA, USA), an orphan
drug based on a recombinant form of the enzyme lysosomal acid lipase (LAL) for treatment
of lysosomal acid lipase deficiency (LAL-D) produced in egg whites. Although regulatory
approval for novel platforms is challenging, the growing number of approved products
from transgenic animals makes a significant contribution in terms of regulatory issues,
demonstrating that these platforms can meet regulatory requirements.
While there are numerous examples of therapeutic molecules produced in transgenic
animals, antigen production is still limited. Nevertheless, this system allows for the
production of complex molecules with sophisticated post-translational modification and
could be of great utility for expression of problematic antigens such as the malaria major
surface protein (MSP-1), which has been already successfully expressed in transgenic goats
for the production of a candidate vaccine [257].
6.4. Insects
Baculovirus expression vector system (BEVS) is not only limited to insect cells cultures;
insect larvae or pupae can also be used for recombinant protein production. Industrial
manufacturing using insect cells, as with any other cultured cells, requires artificial media
and the use of expensive bioreactors. Protein expression using insect larvae as biofactories
offers a cost-effective alternative to insect cells bioreactors and the capacity to produce
large and multiple proteins with an easy scale-up production. This system offers several
advantages, such as high protein expression levels with post-translational modifications of
complex proteins. Although the glycosylation pattern differs from that of mammalian cells,
as previously mentioned for insect cells, bioactive molecules can be efficiently expressed in
this system. Nevertheless, downstream processing to obtain antigens from insects could
be more complex than those established for culture cells. Autographa californica multiple
nucleopolyhedrovirus (AcMNPV) and Bombyx mori nucleopolyhedrovirus (BmNPV) are
the most extensively used vectors in the BEVS to produce heterologous proteins in insect
larvae. The dominant species of insect larvae are the silkworm Bombyx mori (B. mori) and the
cabbage looper Trichoplusia ni (T. ni). Production of human alpha-interferon (IFN-alpha) in
larvae of the silkworm B. mori was published in 1985 [258] and since then many recombinant
proteins have been properly expressed in insects. Recombinant feline IFN omega produced
in silkworms (Virbagen® Omega; Virbac, Carros, France) has been approved for feline
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calicivirus infections in Europe and Canada, while Interdog™, a drug composed of canine
IFN gamma for the treatment of canine atopic dermatitis, was marketed in Japan in
December 2005 [159]. Recently, an efficient application of a baculovirus–silkworm larvae
expression system for PCV2 VLP production has been described [259]. T. ni larvae has also
be reported as host for production of vaccine candidates against PCV2 [260], West Nile virus
(WNV) [261], RHDV [262] and Influenza [263], among others. A comparative analysis of the
expression of L1 HPV protein in T. ni showed that the yield obtained in larvae was 2.5 times
the L1 production yield obtained in insect cells and 5 times the production yield obtained
in transplastomic tobacco plants, referred as g of fresh biomass [264]. Yield of expression
of up to 2 mg of recombinant protein per larvae has been reported for T. ni as expression
system [262]. Protein expression in T. ni pupae has also emerged as an innovative platform
and expression of several proteins have been reported, reaching productivities on the range
of milligrams per infected pupa [265]. As with transgenic animals, a societal debate also
comes up regarding the use of biotechnology in insects; however, this platform allows
for heterologous protein expression with no need to genetically modify the host genome.
Regarding good manufacturing practice (GMP) compliance, upstream processes related
to insect growing, as in the case of whole-plant systems, require special attention to meet
classical GMP criteria based on bioreactors.
Insect larvae and pupae have also attracted the interest in the field of oral vaccines
and silkworm B. mori has been studied as a feasible delivery system for vaccines [266,267].
While the data collected so far support the possible use of baculovirus–silkworm vaccines
as a promising edible vaccine platform, nowadays it is only approved for food ingestion in
a few Asian countries [34].
6.5. Plant-Based Systems
Plants show high potential as bioreactors for recombinant protein production because
they allow the production of properly folded complex proteins and represent an alternative,
cost-effective eukaryotic system [159]. Plant expression platform diversity includes whole
plants, suspension cells, hairy roots, moss, duckweed and microalgae [268]. Differential
glycosylation respect to the native antigen should be taken into consideration when us-
ing this system [269]. Plant proteins lack the terminal galactose and sialic acid residues
commonly found in animals and possess α-(1,3) fucose and β-(1,2) xylose that animal
proteins lack. As a result, glycoproteins from plants can lead to immune reactions and alter
pharmacokinetic properties [256]. Nevertheless, glycoengineering approaches to avoid
plant glycosylation or add human glycosylation can be used when this factor is crucial for
antigen functionality or safety [270]. Plants can be genetically engineered to transiently
or stably express antigens in the nucleus or in the chloroplast. Nuclear expression offers
high biosynthetic capacity and complex post-translational modifications can be performed,
while chloroplast transformation offers high levels of transgene expression (up to 70%
of total soluble proteins) [271,272] but possesses rudimentary prokaryote-like expression
pathways, lacking post-translational modifications such as glycosylation [159]. Stable
expression is preferred in order to obtain a stable genetic resource; however, this method
is time-consuming [273] and can lead to low expression yields [274]. On the other hand,
transient expression technology that uses either Agrobacterium or viral vectors is robust,
quick and easy to manipulate [275] but is typically more unstable [276]. Furthermore,
the production timeline between antigen cloning and large-scale production is very short,
and it only uses the plant as a substrate, without the need to classify it as a Genetically
Modified Organism (GMO). Some of the limitations of the use of plant expression systems
for the production of vaccines are the long timelines involved with the establishment of
transgenic plants, low expression levels and relatively weak efficacy [277], representing a
challenge for economic feasibility. Recent advances in transient expression achieved by
recombinant viral vectors, such as Agrobacterium-mediated expression systems including
Icon Genetics’ magnICON expression technology (magnifection), has led to a great increase
in yields of protein expression. By using this technology in Nicotiana benthamiana, high
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levels of proteins can be achieved in weeks. An example of vaccine generation is the
production of personalized idiotypic vaccines for follicular lymphoma. Purified antibodies
were chemically linked to the carrier protein keyhole limpet hemocyanin (KLH) to form a
conjugate vaccine that was evaluated in a phase I safety and immunogenicity clinical study.
Results showed that 82% of patients displayed a vaccine-induced, idiotype-specific cellular
and/or humoral immune response. Another example is Zmapp monoclonal antibodies
against Ebola, using the large-scale Rapid Antibody Manufacturing Platform (RAMP)
and magnICON vectors. In preclinical studies, they showed to be able to rescue 100% of
rhesus macaques when treatment was initiated up to 5 days post-challenge, improving
the efficacy of any other therapeutics described so far [278]. Advantages of plants over
microbial systems include manufacturing processes that do not require expensive reactors
for biomass production and the possibility to scale-up the process in greenhouses. Another
advantage is low-cost production, estimated to be 10–50 times lower than products derived
from E. coli and 140 times lower than production using baculovirus-based insect cells [279].
Tusé and colleagues described a deep analysis of costs of manufacturing in Nicotiana host
plants of enzymes for diverse applications including a butyrylcholinesterase (rBuChE) for
use as a medical countermeasure [280]. Their analyses indicate that cost advantages over
alternative platforms can be achieved with plant systems, but also that these advantages
depend on the molecule and the relative cost-efficiencies of alternative sources of the same
product. Estimations for rBuChE indicate that a dose of 400 mg could be obtained by
approximately $234 if an existing toll-manufacturing facility were available, a number
significantly below the costs obtainable with blood-extraction processes and substantially
lower than those for transgenic approaches [281]. Additional reports estimate that recom-
binant proteins could be produced in plants at 2–10% of the cost of microbial fermentation
systems and at 0.1% of the cost of mammalian cell cultures [282,283]. A great comparison
of the cost, applicability, production time, scalability and regulatory compliance of different
plant-based platforms is described by Xu and colleagues [268]. Compared with the other
plant-based platforms, plant cells are more suitable to the pharmaceutical industry with
fewer regulatory and environmental concerns [284]. On the other hand, stable transgenic
plants face the major regulatory drawbacks mainly related to GMO environmental con-
cerns. There are also different GMP concerns for products produced from whole plants.
Contained, sterile environment used for plant cells in bioreactors meet the same GMP
criteria of cell-based platforms, but significant changes are required to adapt for proteins
produced in whole-plant systems [285].
Licensed product for human health manufactured in plant-based systems are biologics,
as is the case of Elelyso® (Pfizer, New York, USA), a therapeutic recombinant human
glucocerebrosidase enzyme taliglucerase alfa produced in carrot-cell suspension culture
that was approved by the FDA in 2014 to treat Gaucher disease [286–288]. One of the
most promising platforms for vaccine development is Proficia™, a proprietary technology
of Medicago that uses Nicotiana benthamiana plants as manufacturing platform. A phase
3 clinical study using a plant-derived VLP quadrivalent influenza vaccine was recently
completed, reporting that the vaccine candidate can provide substantial protection against
influenza viruses in adults [289]. More recently, Medicago and GSK announced positive
interim phase 2 results for adjuvanted plant-derived VLP COVID-19 vaccine candidate
while phase 3 clinical study is ongoing (NCT04636697). Regarding veterinary vaccines,
Dow Agro Sciences (Indianapolis, Indiana, USA) obtained United States Department of
Agriculture (USDA) approval in 2006 for a plant-cell-culture-based vaccine for poultry
against Newcastle disease virus. The vaccine was composed of recombinant hemagglutinin–
neuraminidase protein expressed in transgenic tobacco suspension cells [290]. Although the
company finally did not commercialize the product, USDA approval defined a landmark
success in plant-derived vaccine development. Moreover, many other recombinant viral
proteins for human or veterinary diseases produced in plant systems have been tested,
including human immunodeficiency virus, Ebola, rotavirus, Japanese encephalitis, foot-
and-mouth disease virus and bovine viral diarrhea virus [291,292].
Biomolecules 2021, 11, 1072 20 of 33
Owing to the fact that plants are edible, they could also serve as delivery vehicle
for oral vaccination, leading to reduced productions costs as purification steps could be
avoided. This system also offers advantages in terms of storage due to the high stability of
the expressed antigens bio-encapsulated within the cell wall of plant cells. Standardization
of antigen dose is a key aspect because the concentration of antigen in different parts of
plant could not be the same making difficult to standardize vaccine dose [292]. Furthermore,
another important challenge is the lack of a proper dosing strategy, because it has been
reported that low doses may not be able to induce a sufficient immune response, while
high doses may lead to immune tolerance [34].
6.6. Microalgae
Microalgae are also of great interest as alternative systems for production of bio-
pharmaceuticals. The species explored thus far include photosynthetic microalgae such
as Chlamydomonas reinhardtii (C. reinhardtii), Phaeodactylum tricornutum, Dunaliella salina
(D. salina) and Chlorella vulgaris and non-photosynthetic microalgae such as Schizochytrium
sp. [293]. They show particular advantages, including rapid transformation, high growth
rate, ease of cultivation and the ability to perform post-transcriptional modifications and
properly fold complex proteins [294]. Microalgae can be cultivated in very low-cost cul-
ture media, especially in the case of photosynthetic algae that have minimal nutritional
requirements. It is expected that the production of algae-derived biopharmaceuticals will
represent similar savings to those estimated for plant-based platforms when comparing
to microbial fermentation or mammalian cell cultures [293]. This system also offers high
safety profile since they lack toxic endogenous compounds and they do not have risk of
animal pathogens contamination. However, some disadvantages of this system include low
expression levels and improper glycosylation of proteins [295]. Production in chloroplasts
can be successfully performed, but the use of nucleus-based expression, which offers the
production of more complex proteins, has yet to be optimized to reach high yields. Current
yields in chloroplast expression are typically in the 0.02–2% of total soluble protein range
(∼0.03–3 mg/L of culture medium) [293]. C. reinhardtii is the most widely used microal-
gae and several molecular genetic tools are available for this species, including a fully
sequenced genome, methods for transformation and mutagenesis, and vectors for secreted
or non-secreted recombinant protein production [159]. Vaccine candidates expressed in
microalgae are also of great interest for oral administration and numerous reports have
identified algae-derived compounds as immunomodulatory molecules. In addition, the
algae cell wall serves as bioencapsulation, preventing antigen degradation by enzymes
of the gastrointestinal tract [296]. In regard to regulatory aspects, it is also of importance
that microalgae as C. reinhardtii are accepted as GRAS by the FDA. Current candidates
against human diseases expressed in microalgae include vaccines candidates produced
in C. reinhardtii against malaria [297] or human papillomavirus and vaccine candidates
produced in Schizochytrium sp. against influenza [298] or Zika virus [299]. Regarding
veterinary use, a vaccine candidate produced in D. salina against the white spot syndrome
virus was reported to significantly reduce the mortality of orally immunized crayfish [300].
A great summary of microalgae characteristics and biopharmaceuticals produced against
human and animal diseases is discussed by Rosales Mendoza and colleagues [293].
7. Conclusions
Vaccination has been irrefutability useful in the reduction and control of infectious
diseases and is still one of the most important strategies to prevent millions of deaths
worldwide. All through history, traditional vaccines based on live-attenuated or inacti-
vated pathogens have allowed for the successful prevention of several diseases, even the
eradication of smallpox caused by variola virus (VARV) and rinderpest caused by the
rinderpest virus (RPV). Nevertheless, they pose drawbacks, and besides safety concerns
related to the potential to revert to pathogenic forms, they possess limitations in regard
to manufacturing capabilities. Although production processes are well-defined on the
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basis of previous developments, the production of large volumes of pathogens are re-
quired, leading to lengthy manufacturing procedures and a significant lag time between
vaccine production and delivery. Production capability also meets limitations when a high
number of doses are required, as in the recent COVID-19 pandemic. Construction and
commission of a vaccine manufacturing facility is so costly and lengthy, that when peaks
of production are required, capabilities are dependent on the limited existing facilities.
Furthermore, one of the biggest weaknesses of traditional vaccines is that not all infectious
pathogens can be easily cultured, encountering difficulties to address multiple infectious
diseases. This problem was partially solved with the emergence of recombinant subunit
vaccines. Advances in antigen design and the understanding of their interaction with the
immune system in combination with the establishment of recombinant systems for protein
expression opened the door to the development of new vaccine candidates for infectious
diseases that still had no treatment. Moreover, although subunit vaccines tend to reduce
immunogenicity when compared to live vaccines, several approaches are being explored
to enhance their efficacy. The great potential of recombinant vaccines resides in the ability
to rationally design antigenic sequences. Availability of multiple genome sequences, in
addition to bioinformatics tools that enable prediction of antigenic regions and protein
structure, allows for the in silico design of sequences for vaccine candidates. What is more,
nanotechnology and nanoparticle design for antigen display are leading technologies
in recent advances for recombinant vaccine development. One of the main limitations
of current vaccine-manufacturing technologies is that they are restricted to producing
only one vaccine or a very narrow range of vaccines. Thus, individual manufacturing
processes need to be developed for each vaccine, making vaccine development costly, time-
consuming and restricted. Platform technologies allow for the standardization of upstream
and downstream processes, given that the platform base remains unchanged. Although
certain processes would require optimization, these systems provide flexibility, the possi-
bility for multi-product facilities and rapid responses against emerging challenges, such as
pandemic emergencies. Considering protein-based vaccines, antigen display systems are
potential candidates as vaccine platforms. They permit standardization of manufacturing
processes by using a versatile platform that could react fast against emerging necessities.
The route of administration of vaccines is also a pivotal aspect, not just for improvement
of immunity, but also to solve the bottlenecks of demanding resources for the massive
administration of injectable vaccines. We can easily perceive the positive impact that orally
administered COVID-19 vaccines would have, as they would not require trained personnel
for their administration. Platforms for heterologous protein production are also key aspect
in vaccine development. Some of the selection criteria for protein expression platforms are
cost and time for development and production processes, and molecular requirements of
antigens (disulfide bonds, glycosylation, secretion, assembly of protein complexes, etc.). In
general terms, the more complex the antigen to be expressed, the more sophisticated the
platform required.
Traditional platforms for recombinant expression such as bacteria, yeast or insect cells
have permitted the production of the currently available subunit vaccines for human and
animal use. Bacterial expression systems, particularly the one based on the dominant-strain
E. coli, offer advantages, such as high speed of production and high yields of expression at
reduced costs, but they also have limitations in the expression of complex proteins, because
post-transcriptional eukaryotic modifications cannot be performed. Although the hepatitis
E vaccine for human use and canine leishmaniasis or feline leukemia veterinary vaccines
are produced in this system, the number of products in the market is still limited, most
likely due to the fact that complex proteins are usually required as vaccine candidates. Thus,
yeast and insect cells are the preferred platforms form human vaccine production and for
expression of assembled antigens, such as VLPs. Concerning animal health, the insect cell
is notably the dominant platform for recombinant vaccine manufacturing. Although a great
number of biopharmaceuticals, such as therapeutic antibodies, are currently produced
in mammalian cells, the number of marketed vaccines is still limited due to the higher
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costs and requirements associated with development and manufacture with this system.
Nonetheless, a human vaccine against herpes zoster virus produced in CHO cells was
recently approved for commercialization by EMA and FDA.
Alternative production platforms that can overcome all the mentioned limitations
in vaccine production are being increasingly demanded. Bacteria and yeast are being
engineered to decrease cost and time of production and to improve expression yields and
complexity of heterologous proteins. Pressing demands of cost-effective platforms for vac-
cine production have led to the emergence of alternative systems, such as insects or plants.
These platforms circumvent the use of expensive bioreactors and culture media, minimiz-
ing manufacturing requirements. One of the main disadvantages of the plant system is
the long period involved with the establishment of transgenic plants. Furthermore, high
yield expression of complex proteins is still challenging. Whole plants and plant cells have
been widely explored for expression of therapeutic proteins, and a therapeutic recombinant
human glucocerebrosidase enzyme produced in carrot cells is already commercialized.
Insect pupae and larvae are emerging as promising systems for protein production due to
their capability to express complex proteins with high yields. The use of insects as single
bioreactors offers versatility and easy scale-up, simplifying the requirements to construct
and equip a vaccine-manufacturing facility. Although just two biologics produced in
insect larvae are marketed at the moment, several vaccines candidates are under devel-
opment showing promising results as an alternative platform for vaccine development.
As a final point, the algae expression system has also appeared as a promising platform
for cost-effective production of proteins, due to the high growth rate and low require-
ments; however, optimization of nuclear expression is still required to achieve high-yield
expression of complex proteins. The final suitability of the abovementioned platforms will
depend on the nature of the vaccine candidates. Although these platforms and technologies
have emerged as promising alternatives to vaccine production, further effort is required,
especially regarding the reduction of costs and time associated with vaccine development.
The recent COVID-19 pandemic has revealed the importance of quick responses to vaccine
manufacturing, as well as that the time required for vaccine development and delivery is
critical. To achieve this goal, flexible and versatile vaccine-manufacturing platforms are
essential to overcome current and future vaccination demands.
Author Contributions: Conceptualization, R.C. and J.B.; writing—original draft preparation, R.C.;
writing—review and editing, R.C. and J.B. All authors have read and agreed to the published version
of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Needham, J. China and the origins of immunology. East. Horiz. 1980, 19, 6–12. [PubMed]
2. Jenner, E. An Inquiry into the Causes and Effects of the Variole Vaccinae, a Disease Discovered in Some of the Western Counties of England,
Particularly Gloucestershire and Known by the Name of the Cow-Pox; Sampson Low: London, UK, 1798.
3. Bartlett, B.L.; Pellicane, A.J.; Tyring, S.K. Vaccine Immunology. Dermatol. Ther. 2009, 22, 104–109. [CrossRef] [PubMed]
4. Pasteur, L. De l’attenuation du virus du choléra des poules. CR Acad. Sci. Paris 1880, 91, 673–680.
5. Pasteur, L. Méthode pour prévenir la rage après morsure. CR Acad. Sci. Paris 1885, 101, 765–772.
6. D’Amelio, E.; Salemi, S.; D’Amelio, R. Anti-Infectious Human Vaccination in Historical Perspective. Int. Rev. Immunol. 2016, 35,
260–290. [CrossRef] [PubMed]
7. De Gregorio, E.; Rappuoli, R. From empiricism to rational design: A personal perspective of the evolution of vaccine development.
Nat. Rev. Immunol. 2014, 14, 505–514. [CrossRef]
8. Karch, C.P.; Burkhard, P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem.
Pharmacol. 2016, 120, 1–14. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 23 of 33
9. Berg, P.; Mertz, J.E. Personal reflections on the origins and emergence of recombinant DNA technology. Genetics 2010, 184, 9–17.
[CrossRef] [PubMed]
10. Dahl-Hansen, E.; Siebke, J.C.; Frøland, S.S.; Degré, M. Immunogenicity of yeast-derived hepatitis B vaccine from two different
producers. Epidemiol. Infect. 1990, 104, 143–149. [CrossRef] [PubMed]
11. World Health Organization. Available online: https:/www.who.int/news-room/facts-in-pictures/detail/immunization
(accessed on 15 May 2021).
12. Ryan, M.P.; Walsh, G. Veterinary-based biopharmaceuticals. Trends Biotechnol. 2012, 30, 615–620. [CrossRef]
13. Capps, B.; Lederman, Z. One Health, Vaccines and Ebola: The Opportunities for Shared Benefits. J. Agric. Environ. Ethics 2015, 28,
1011–1032. [CrossRef] [PubMed]
14. Jiskoot, W.; Kersten, G.F.A.; Mastrobattista, E.; Slütter, B. Vaccines. In Pharmaceutical Biotechnology; Crommelin, D.J.A., Sindelar,
R.D., Meibohm, B., Eds.; Springer International Publishing: Cham, Switzerland, 2019; Volume 14, pp. 281–304. ISBN 978-3-030-
00709-6.
15. Siegrist, C.-A. Vaccine immunology. In Vaccines, 6th ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2013; pp. 14–32.
ISBN 9781455700905.
16. Geeraedts, F.; Goutagny, N.; Hornung, V.; Severa, M.; De Haan, A.; Pool, J.; Wilschut, J.; Fitzgerald, K.A.; Huckriede, A. Superior
immunogenicity of inactivated whole virus h5n1 influenza vaccine is primarily controlled by toll-like receptor signalling. PLoS
Pathog. 2008, 4, e1000138. [CrossRef] [PubMed]
17. Moser, M.; Leo, O. Key concepts in immunology. Vaccine 2010, 28, C2–C13. [CrossRef] [PubMed]
18. Wang, J.; Thorson, L.; Stokes, R.W.; Santosuosso, M.; Huygen, K.; Zganiacz, A.; Hitt, M.; Xing, Z. Single Mucosal, but Not
Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis.
J. Immunol. 2004, 173, 6357–6365. [CrossRef]
19. Lycke, N.; Bemark, M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other
ADP-ribosylating toxins. Mucosal Immunol. 2010, 3, 556–566. [CrossRef] [PubMed]
20. Wallis, J.; Shenton, D.P.; Carlisle, R.C. Novel approaches for the design, delivery and administration of vaccine technologies. Clin.
Exp. Immunol. 2019, 196, 189–204. [CrossRef]
21. Azizi, A.; Kumar, A.; Diaz-Mitoma, F.; Mestecky, J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog.
2010, 6, e100114. [CrossRef] [PubMed]
22. Newsted, D.; Fallahi, F.; Golshani, A.; Azizi, A. Advances and challenges in mucosal adjuvant technology. Vaccine 2015, 33,
2399–2405. [CrossRef]
23. Mitragotri, S.; Burke, P.A.; Langer, R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery
strategies. Nat. Rev. Drug Discov. 2014, 13, 655–672. [CrossRef]
24. Wang, S.; Liu, H.; Zhang, X.; Qian, F. Intranasal and oral vaccination with protein-based antigens: Advantages, challenges and
formulation strategies. Protein Cell 2015, 6, 480–503. [CrossRef] [PubMed]
25. Czerkinsky, C.; Holmgren, J. Vaccines against enteric infections for the developing world. Philos. Trans. R. Soc. B Biol. Sci. 2015,
370, 20150142. [CrossRef] [PubMed]
26. Nascimento, I.P.; Leite, L.C.C. Recombinant vaccines and the development of new vaccine strategies. Brazilian J. Med. Biol. Res.
2012, 45, 1102–1111. [CrossRef]
27. Rosales-Mendoza, S.; Angulo, C.; Meza, B. Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends
Biotechnol. 2016, 34, 124–136. [CrossRef] [PubMed]
28. Velasquez, L.S.; Shira, S.; Berta, A.N.; Kilbourne, J.; Babu, M.; Tizard, I.; Ni, Y.; Arntzen, C.J.; Herbst-kralovetz, M.M. Intranasal
delivery of Norwalk virus-like particles formulated in an in-situ gelling, dry powder vaccine. Vaccine 2011, 29, 5221–5231.
[CrossRef]
29. Garg, N.K.; Mangal, S.; Khambete, H.; Sharma, P.K.; Tyagi, R.K. Mucosal Delivery of Vaccines: Role of Mucoadhe-
sive/Biodegradable Polymers. Recent Pat. Drug Deliv. Formul. 2010, 4, 114–128. [CrossRef]
30. Kim, T.; Kim, S.H.; Lee, M.-G. The Origin of Skin Dendritic Cell Network and Its Role in Psoriasis. Int. J. Mol. Sci. 2018, 19, 42.
[CrossRef]
31. Mikszta, J.A.; Laurent, P.E. Cutaneous delivery of prophylactic and therapeutic vaccines: Historical perspective and future
outlook. Expert Rev. Vaccines 2008, 7, 1329–1339. [CrossRef]
32. Marshall, S.; Sahm, L.J.; Moore, A.C.; Marshall, S.; Sahm, L.J.; Moore, A.C. The success of microneedle-mediated vaccine delivery
into skin. Hum. Vaccin. Immunother. 2016, 12, 2975–2983. [CrossRef] [PubMed]
33. Kenney, R.T.; Frech, S.A.; Muenz, L.R.; Villar, C.P.; Glenn, G.M. Dose Sparing with Intradermal Injection of Influenza Vaccine. N.
Engl. J. Med. 2004, 351, 2295–2301. [CrossRef] [PubMed]
34. Criscuolo, E.; Caputo, V.; Diotti, R.A.; Sautto, G.A.; Kirchenbaum, G.A.; Clementi, N. Alternative methods of vaccine delivery:
An overview of edible and intradermal vaccines. J. Immunol. Res. 2019, 8303648. [CrossRef]
35. Li, G.M.; Chiu, C.; Wrammert, J.; McCausland, M.; Andrews, S.F.; Zheng, N.Y.; Lee, J.H.; Huang, M.; Qu, X.; Edupuganti, S.; et al.
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc.
Natl. Acad. Sci. USA 2012, 109, 9047–9052. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 24 of 33
36. Chen, M.W.; Cheng, T.J.R.; Huang, Y.; Jan, J.T.; Ma, S.H.; Yu, A.L.; Wong, C.H.; Ho, D.D. A consensus—Hemagglutinin-based
DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. USA 2008, 105, 13538–13543.
[CrossRef]
37. Perelberg, A.; Ronen, A.; Hutoran, M.; Smith, Y.; Kotler, M. Protection of cultured Cyprinus carpio against a lethal viral disease by
an attenuated virus vaccine. Vaccine 2005, 23, 3396–3403. [CrossRef] [PubMed]
38. Francis, M.J. Recent Advances in Vaccine Technologies. Vet. Clin. North Am. Small Anim. Pract. 2018, 48, 231–241. [CrossRef]
[PubMed]
39. Zhou, X.; Jiang, X.; Qu, M.; Aninwene, G.E.; Jucaud, V.; Moon, J.J.; Gu, Z.; Sun, W.; Khademhosseini, A. Engineering antiviral
vaccines. ACS Nano 2020, 14, 12370–12389. [CrossRef]
40. Ura, T.; Yamashita, A.; Mizuki, N.; Okuda, K.; Shimada, M. New vaccine production platforms used in developing SARS-CoV-2
vaccine candidates. Vaccine 2021, 39, 197–201. [CrossRef] [PubMed]
41. Ganguly, S.; Padhy, A.; Para, P.A.; Pandey, A.K.; Praveen, P.K.; Wakchaure, R.; Sahu, A.R. DIVA Vaccines: A Brief Review on its
Novel Facets for the Eradication of Infections of Livestock and Poultry. World J. Clin. Pharmacol. Microbiol. Toxicol. 2015, 1, 22–23.
42. Uddowla, S.; Hollister, J.; Pacheco, J.M.; Rodriguez, L.L.; Rieder, E. A Safe Foot-and-Mouth Disease Vaccine Platform with Two
Negative Markers for Differentiating Infected from Vaccinated Animals. J. Virol. 2012, 86, 11675–11685. [CrossRef]
43. Steel, J.; Lowen, A.C.; Pena, L.; Angel, M.; Solórzano, A.; Albrecht, R.; Perez, D.R.; García-Sastre, A.; Palese, P. Live Attenuated
Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza. J. Virol.
2009, 83, 1742–1753. [CrossRef]
44. Charlton Hume, H.K.; Lua, L.H.L. Platform technologies for modern vaccine manufacturing. Vaccine 2017, 35, 4480–4485.
[CrossRef]
45. Vela Ramirez, J.E.; Sharpe, L.A.; Peppas, N.A. Current state and challenges in developing oral vaccines. Adv. Drug Deliv. Rev.
2017, 114, 116–131. [CrossRef] [PubMed]
46. Lauring, A.S.; Jones, J.O.; Andino, R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 2010, 28,
573–579. [CrossRef] [PubMed]
47. Raghavan, S.; Hjulström, M.; Holmgren, J.; Svennerholm, A.M. Protection against experimental Helicobacter pylori infection after
immunization with inactivated H. pylori whole-cell vaccines. Infect. Immun. 2002, 70, 6383–6388. [CrossRef] [PubMed]
48. Summerton, N.A.; Welch, R.W.; Bondoc, L.; Yang, H.H.; Pleune, B.; Ramachandran, N.; Harris, A.M.; Bland, D.; Jackson, W.J.;
Park, S.; et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine
adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010, 28, 1404–1411. [CrossRef] [PubMed]
49. Rappuoli, R.; De Gregorio, E.; Costantino, P.; Smith, D.; Anderson, P.; Anderson, P.; Smith, D. On the mechanisms of conjugate
vaccines. Proc. Natl. Acad. Sci. USA 2019, 116, 14–16. [CrossRef] [PubMed]
50. Kushnir, N.; Streatfield, S.J.; Yusibov, V. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and
production systems and advances in clinical development. Vaccine 2012, 31, 58–83. [CrossRef] [PubMed]
51. Herzog, C.; Hartmann, K.; Künzi, V.; Kürsteiner, O.; Mischler, R.; Lazar, H.; Glück, R. Eleven years of Inflexal® V-a virosomal
adjuvanted influenza vaccine. Vaccine 2009, 27, 4381–4387. [CrossRef] [PubMed]
52. Bovier, P.A. Epaxal®: A virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 2008, 7, 1141–1150. [CrossRef]
[PubMed]
53. Kaurav, M.; Madan, J.; Sudheesh, M.S.; Pandey, R.S. Combined adjuvant-delivery system for new generation vaccine antigens:
Alliance has its own advantage. Artif. Cells Nanomed. Biotechnol. 2018, 46, S818–S831. [CrossRef] [PubMed]
54. Micoli, F.; Maclennan, C.A. Outer membrane vesicle vaccines. Semin. Immunol. 2020, 50, 101433. [CrossRef]
55. Ura, T.; Okuda, K.; Shimada, M. Developments in viral vector-based vaccines. Vaccines 2014, 2, 624–641. [CrossRef] [PubMed]
56. Robert-Guroff, M. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 2007, 18, 546–556.
[CrossRef] [PubMed]
57. Ewer, K.; Sebastian, S.; Spencer, A.J.; Gilbert, S.; Hill, A.V.S.; Lambe, T. Chimpanzee adenoviral vectors as vaccines for outbreak
pathogens. Hum. Vaccines Immunother. 2017, 13, 3020–3032. [CrossRef] [PubMed]
58. Geisbert, T.W.; Bailey, M.; Hensley, L.; Asiedu, C.; Geisbert, J.; Stanley, D.; Honko, A.; Johnson, J.; Mulangu, S.; Pau, M.G.;
et al. Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman
Primates against Ebolavirus Challenge. J. Virol. 2011, 85, 4222–4233. [CrossRef] [PubMed]
59. Dicks, M.D.J.; Spencer, A.J.; Edwards, N.J.; Wadell, G.; Bojang, K.; Gilbert, S.C.; Hill, A.V.S.; Cottingham, M.G. A novel chimpanzee
adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity.
PLoS ONE 2012, 7, e40385. [CrossRef]
60. Weli, S.C.; Tryland, M. Avipoxviruses: Infection biology and their use as vaccine vectors. Virol. J. 2011, 8, 49. [CrossRef]
61. Poulet, H.; Minke, J.; Pardo, M.C.; Juillard, V.; Nordgren, B.; Audonnet, J.C. Development and registration of recombinant
veterinary vaccines. The example of the canarypox vector platform. Vaccine 2007, 25, 5606–5612. [CrossRef]
62. Sánchez-Sampedro, L.; Perdiguero, B.; Mejías-Pérez, E.; Garcías-Arriaza, J.; Di Pilato, M.; Esteban, M. The Evolution of Poxvirus
Vaccines. Viruses 2015, 7, 1726–1803. [CrossRef]
63. Gary, E.N.; Weiner, D.B. DNA vaccines: Prime time is now. Curr. Opin. Immunol. 2020, 65, 21–27. [CrossRef]
64. Amanat, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020, 52, 583–589. [CrossRef]
Biomolecules 2021, 11, 1072 25 of 33
65. Pierini, S.; Perales-linares, R.; Uribe-herranz, M.; Pol, J.G.; Zitvogel, L. Trial watch: DNA-based vaccines for oncological indications.
Oncoimmunology 2017, 6, e1398878. [CrossRef] [PubMed]
66. Lu, S. Immunogenicity of DNA vaccines in humans: It takes two to tango. Hum. Vaccines 2008, 4, 449–452. [CrossRef] [PubMed]
67. Suschak, J.J.; Williams, J.A.; Schmaljohn, C.S. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and
molecular adjuvants to increase immunogenicity. Hum. Vaccines Immunother. 2017, 13, 2837–2848. [CrossRef]
68. Bai, H.; Lester, G.M.S.; Petishnok, L.C.; Dean, D.A. Cytoplasmic transport and nuclear import of plasmid DNA. Biosci. Rep. 2017,
37, BSR20160616. [CrossRef] [PubMed]
69. Ada, G. Vaccines and vaccination. N. Engl. J. Med. Rev. 2001, 345, 1042–1053. [CrossRef] [PubMed]
70. Faurez, F.; Dory, D.; Le Moigne, V.; Gravier, R.; Jestin, A. Biosafety of DNA vaccines: New generation of DNA vectors and current
knowledge on the fate of plasmids after injection. Vaccine 2010, 28, 3888–3895. [CrossRef]
71. Tombácz, I.; Weissman, D.; Pardi, N. Vaccination with Messenger RNA: A Promising Alternativeto DNA Vaccination. Methods
Mol. Biol. 2021, 2197, 13–31. [CrossRef]
72. Let’s talk about lipid nanoparticles. Nat. Rev. Mater. 2021, 6. [CrossRef]
73. Schoenmaker, L.; Witzigmann, D.; Kulkarni, J.A.; Verbeke, R.; Kersten, G.; Jiskoot, W.; Crommelin, D.J.A. mRNA-lipid nanoparticle
COVID-19 vaccines: Structure and stability. Int. J. Pharm. 2021, 601, 120586. [CrossRef]
74. Evers, M.J.W.; Kulkarni, J.A.; van der Meel, R.; Cullis, P.R.; Vader, P.; Schiffelers, R.M. State-of-the-Art Design and Rapid-Mixing
Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery. Small Methods 2018, 2, 1700375. [CrossRef]
75. Reichmuth, A.M.; Oberli, M.A.; Jeklenec, A.; Langer, R.; Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles. Ther.
Deliv. 2016, 7, 319–334. [CrossRef] [PubMed]
76. Brader, M.L.; Williams, S.J.; Banks, J.M.; Hui, W.H.; Zhou, Z.H.; Jin, L. Encapsulation state of messenger RNA inside lipid
nanoparticles. Biophys. J. 2021, 1–5. [CrossRef]
77. Kulkarni, J.A.; Darjuan, M.M.; Mercer, J.E.; Chen, S.; Van Der Meel, R.; Thewalt, J.L.; Tam, Y.Y.C.; Cullis, P.R. On the Formation and
Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano 2018, 12, 4787–4795. [CrossRef]
78. Arteta, M.Y.; Kjellman, T.; Bartesaghi, S.; Wallin, S.; Wu, X.; Kvist, A.J.; Dabkowska, A.; Székely, N.; Radulescu, A.; Bergenholtz, J.;
et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
Proc. Natl. Acad. Sci. USA 2018, 115, E3351–E3360. [CrossRef] [PubMed]
79. Aldosari, B.N.; Alfagih, I.M.; Almurshedi, A.S. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics
2021, 13, 206. [CrossRef]
80. Presnyak, V.; Alhusaini, N.; Chen, Y.H.; Martin, S.; Morris, N.; Kline, N.; Olson, S.; Weinberg, D.; Baker, K.E.; Graveley, B.R.; et al.
Codon optimality is a major determinant of mRNA stability. Cell 2015, 160, 1111–1124. [CrossRef] [PubMed]
81. Thess, A.; Grund, S.; Mui, B.L.; Hope, M.J.; Baumhof, P.; Fotin-Mleczek, M.; Schlake, T. Sequence-engineered mRNA Without
Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol. Ther. 2015, 23, 1456–1464.
[CrossRef]
82. Mauger, D.M.; Joseph Cabral, B.; Presnyak, V.; Su, S.V.; Reid, D.W.; Goodman, B.; Link, K.; Khatwani, N.; Reynders, J.; Moore,
M.J.; et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl. Acad. Sci. USA 2019,
116, 24075–24083. [CrossRef]
83. Tan, M.; Jiang, X. Recent advancements in combination subunit vaccine development. Hum. Vaccines Immunother. 2017, 13,
180–185. [CrossRef]
84. Bobbala, S.; Hook, S. Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? Pharm. Res. 2016, 33,
2078–2097. [CrossRef] [PubMed]
85. Kapsenberg, M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 2003, 3, 984–993. [CrossRef]
86. Hos, B.J.; Tondini, E.; van Kasteren, S.I.; Ossendorp, F. Approaches to improve chemically defined synthetic peptide vaccines.
Front. Immunol. 2018, 9, 884. [CrossRef] [PubMed]
87. Kelly, H.G.; Kent, S.J.; Wheatley, A.K. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev. Vaccines
2019, 18, 269–280. [CrossRef] [PubMed]
88. García, A.; De Sanctis, J.B. An overview of adjuvant formulations and delivery systems. Apmis 2014, 122, 257–267. [CrossRef]
[PubMed]
89. Li, S.W.; Zhang, J.; Li, Y.M.; Ou, S.H.; Huang, G.Y.; He, Z.Q.; Ge, S.X.; Xian, Y.L.; Pang, S.Q.; Ng, M.H.; et al. A bacterially
expressed particulate hepatitis E vaccine: Antigenicity, immunogenicity and protectivity on primates. Vaccine 2005, 23, 2893–2901.
[CrossRef] [PubMed]
90. Zhu, F.C.; Zhang, J.; Zhang, X.F.; Zhou, C.; Wang, Z.Z.; Huang, S.J.; Wang, H.; Yang, C.L.; Jiang, H.M.; Cai, J.P.; et al. Efficacy and
safety of a recombinant hepatitis e vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3
trial. Lancet 2010, 376, 895–902. [CrossRef]
91. Venters, C.L.; Graham, W.J.; Cassidy, W.M.; Denham, S. Recombinant-HB: Perspectives past, present and future. Expert Rev.
Vaccines 2004, 3, 119–129. [CrossRef]
92. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/recombivax-hb
(accessed on 15 May 2021).
93. André FE, S.A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgr. Med.
J. 1987, 63 (Suppl. S2), 169–177.
Biomolecules 2021, 11, 1072 26 of 33
94. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/engerix-b
(accessed on 15 May 2021).
95. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/hbvaxpro (accessed
on 15 May 2021).
96. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix (accessed on
15 May 2021).
97. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/heplisav-b (accessed
on 15 May 2021).
98. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/heplisav-b
(accessed on 15 May 2021).
99. Buckland, B.C. The process development challenge for a new vaccine. Nat. Med. 2005, 11, S16–S19. [CrossRef] [PubMed]
100. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil (accessed
on 1 June 2021).
101. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil
(accessed on 1 June 2021).
102. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9 (accessed
on 1 June 2021).
103. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9
(accessed on 1 June 2021).
104. Rutgers, T.; Gordon, D.; Gathoye, A.M.; Hollingdale, M.; Hockmeyer, W.; Rosenberg, M.; Wilde, M. De Hepatitis B Surface
Antigen as Carrier Matrix for the Repetitive Epitope of the Circumsporozoite Protein of Plasmodium Falciparum. Nat. Biotechnol.
1988, 6, 1065–1070. [CrossRef]
105. European Medicines Agency. Available online: https://www.ema.europa.eu/en/mosquirix-h-w-2300 (accessed on 1 June 2021).
106. Cohen, J.; Nussenzweig, V.; Nussenzweig, R.; Vekemans, J.; Leach, A. From the circumsporozoite protein to the RTS, S/AS
candidate vaccine. Hum. Vaccin. 2010, 6, 90–96. [CrossRef]
107. Kirnbauer, R.; Booy, F.; Cheng, N.; Lowy, D.R.; Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like
particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 1992, 89, 12180–12184. [CrossRef] [PubMed]
108. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix (accessed
on 1 June 2021).
109. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/cervarix
(accessed on 1 June 2021).
110. Cox, M.M.J.; Hollister, J.R. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37, 182–189.
[CrossRef]
111. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok
(accessed on 1 June 2021).
112. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok-
quadrivalent (accessed on 1 June 2021).
113. James, S.F.; Chahine, E.B.; Sucher, A.J.; Hanna, C. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Ann.
Pharmacother. 2018, 52, 673–680. [CrossRef] [PubMed]
114. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix
(accessed on 1 June 2021).
115. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/shingrix (accessed
on 1 June 2021).
116. Marciani, D.J.; Kensil, C.R.; Beltz, G.A.; Hung, C.H.; Cronier, J.; Aubert, A. Genetically-engineered subunit vaccine against feline
leukaemia virus: Protective immune response in cats. Vaccine 1991, 9, 89–96. [CrossRef]
117. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/leucogen
(accessed on 1 June 2021).
118. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/letifend (accessed
on 1 June 2021).
119. Dong, X.N.; Chen, Y.H. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine 2007, 25, 205–230. [CrossRef]
[PubMed]
120. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/porcilis-pesti
(accessed on 1 June 2021).
121. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/advasure
(accessed on 1 June 2021).
122. Fachinger, V.; Bischoff, R.; Jedidia, S.B.; Saalmüller, A.; Elbers, K. The effect of vaccination against porcine circovirus type 2 in pigs
suffering from porcine respiratory disease complex. Vaccine 2008, 26, 1488–1499. [CrossRef] [PubMed]
123. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/ingelvac-
circoflex (accessed on 1 June 2021).
Biomolecules 2021, 11, 1072 27 of 33
124. Animal and Plant Health Inspection Service, U.S. Department of Agriculture. Available online: https://www.aphis.usda.gov/
aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries/vet-label-data/daf5519a-cf42-4c20-bae7-b49284ee2
81a (accessed on 1 June 2021).
125. Animal and Plant Health Inspection Service, U.S. Department of Agriculture. Available online: https://www.aphis.usda.gov/
aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries/vet-label-data/2cfb09f0-0685-4e84-8b43-edded472
c5e2 (accessed on 1 June 2021).
126. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/porcilis-pcv
(accessed on 1 June 2021).
127. Animal and Plant Health Inspection Service, U.S. Department of Agriculture. Available online: https://www.aphis.usda.gov/
aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries/vet-label-data/2f787143-d90d-4054-be26-b5565e3
1d2b3 (accessed on 1 June 2021).
128. European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/reprocyc-
parvoflex (accessed on 1 June 2021).
129. Kanekiyo, M.; Wei, C.J.; Yassine, H.M.; McTamney, P.M.; Boyington, J.C.; Whittle, J.R.R.; Rao, S.S.; Kong, W.P.; Wang, L.; Nabel,
G.J. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499, 102–106.
[CrossRef] [PubMed]
130. Keller, S.; Wilson, J.T.; Patilea, G.I.; Kern, H.B.; Convertine, A.J.; Stayton, P.S. Neutral Polymer Micelle Carriers with pH-
Responsive, Endosome-Releasing Activity Modulate Antigen Trafficking to Enhance CD8 T-Cell Responses. J. Control. Release
2014, 191, 24–33. [CrossRef]
131. Kang, S.; Ahn, S.; Lee, J.; Kim, J.Y.; Choi, M.; Gujrati, V.; Kim, H.; Kim, J.; Shin, E.C.; Jon, S. Effects of gold nanoparticle-based
vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J. Control. Release 2017, 256, 56–67. [CrossRef]
132. Rahimian, S.; Kleinovink, J.W.; Fransen, M.F.; Mezzanotte, L.; Gold, H.; Wisse, P.; Overkleeft, H.; Amidi, M.; Jiskoot, W.; Löwik,
C.W.; et al. Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine:
Invivo tracking and evaluation of antigen-specific CD8+ T cell immune response. Biomaterials 2015, 37, 469–477. [CrossRef]
[PubMed]
133. Baschong, W.; Hasler, L.; Häner, M.; Kistler, J.; Aebi, U. Repetitive versus monomeric antigen presentation: Direct visualization of
antibody affinity and specificity. J. Struct. Biol. 2003, 143, 258–262. [CrossRef] [PubMed]
134. Chackerian, B. Virus-like particles: Flexible platforms for vaccine development. Expert Rev. Vaccines 2007, 6, 381–390. [CrossRef]
135. Grgacic, E.V.L.; Anderson, D.A. Virus-like particles: Passport to immune recognition. Methods 2006, 40, 60–65. [CrossRef]
[PubMed]
136. Keller, S.A.; Bauer, M.; Manolova, V.; Muntwiler, S.; Saudan, P.; Bachmann, M.F. Cutting Edge: Limited Specialization of Dendritic
Cell Subsets for MHC Class II-Associated Presentation of Viral Particles. J. Immunol. 2010, 184, 26–29. [CrossRef] [PubMed]
137. Manolova, V.; Flace, A.; Bauer, M.; Schwarz, K.; Saudan, P.; Bachmann, M.F. Nanoparticles target distinct dendritic cell populations
according to their size. Eur. J. Immunol. 2008, 38, 1404–1413. [CrossRef] [PubMed]
138. Murata, Y.; Lightfoote, P.M.; Rose, R.C.; Walsh, E.E. Antigenic presentation of heterologous epitopes engineered into the outer
surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol. J. 2009, 6, 1–10. [CrossRef]
139. Sällberg, M.; Hughes, J.; Jones, J.; Phillips, T.R.; Milich, D.R. A malaria vaccine candidate based on a hepatitis B virus core
platform. Intervirology 2002, 45, 350–361. [CrossRef]
140. Shchelkunov, S.N.; Salyaev, R.K.; Pozdnyakov, S.G.; Rekoslavskaya, N.I.; Nesterov, A.E.; Ryzhova, T.S.; Sumtsova, V.M.; Pakova,
N.V.; Mishutina, U.O.; Kopytina, T.V.; et al. Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and
human immunodeficiency viruses. Biotechnol. Lett. 2006, 28, 959–967. [CrossRef]
141. Ballou, W.R. The development of the RTS,S malaria vaccine candidate: Challenges and lessons. Parasite Immunol. 2009, 31,
492–500. [CrossRef]
142. Roldão, A.; Silva, A.C.; Mellado, M.C.M.; Alves, P.; Carrondo, M. Viruses and Virus-Like Particles in Biotechnology: Fundamentals
and Applications. Compr. Biotechnol. 2017, 633–656. [CrossRef]
143. Lua, L.H.L.; Fan, Y.; Chang, C.; Connors, N.K.; Middelberg, A.P.J. Synthetic biology design to display an 18kDa rotavirus large
antigen on a modular virus-like particle. Vaccine 2015, 33, 5937–5944. [CrossRef]
144. Tekewe, A.; Fan, Y.; Tan, E.; Middelberg, A.P.J.; Lua, L.H.L. Integrated molecular and bioprocess engineering for bacterially
produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen. Biotechnol. Bioeng. 2017, 114,
397–406. [CrossRef] [PubMed]
145. Brune, K.D.; Leneghan, D.B.; Brian, I.J.; Ishizuka, A.S.; Bachmann, M.F.; Draper, S.J.; Biswas, S.; Howarth, M. Plug-and-Display:
Decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci. Rep. 2016, 6, 1–13. [CrossRef] [PubMed]
146. Thrane, S.; Janitzek, C.M.; Matondo, S.; Resende, M.; Gustavsson, T.; Jongh, W.A.; Clemmensen, S.; Roeffen, W.; Vegte-Bolmer, M.;
Gemert, G.J.; et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J. Nanobiotechnology
2016, 14, 1–16. [CrossRef] [PubMed]
147. Janitzek, C.M.; Matondo, S.; Thrane, S.; Nielsen, M.A.; Kavishe, R.; Mwakalinga, S.B.; Theander, T.G.; Salanti, A.; Sander, A.F.
Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and
durable antibody responses. Malar. J. 2016, 15, 1–9. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 28 of 33
148. Peyret, H.; Gehin, A.; Thuenemann, E.C.; Blond, D.; El Turabi, A.; Beales, L.; Clarke, D.; Gilbert, R.J.C.; Fry, E.E.; Stuart, D.I.; et al.
Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to
accommodate foreign proteins. PLoS ONE 2015, 10, e0120751. [CrossRef]
149. He, D.; Marles-Wright, J. Ferritin family proteins and their use in bionanotechnology. New Biotechnol. 2015, 32, 651–657. [CrossRef]
[PubMed]
150. Lawson, D.M.; Artymiuk, P.J.; Yewdall, S.J.; Smith, J.M.; Livingstone, J.C.; Treffry, A.; Luzzago, A.; Levi, S.; Arosio, P.; Cesareni,
G.; et al. Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature 1991, 349,
541–544. [CrossRef] [PubMed]
151. Rome, L.H.; Kickhoefer, V.A. Development of the Vault Particle as a Platform Technology. ACS Nano 2013, 7, 889–902. [CrossRef]
152. Kedersha, N.L.; Rome, L.H. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single
species of small RNA. J. Cell Biol. 1986, 103, 699–709. [CrossRef]
153. Gabashvili, A.N.; Chmelyuk, N.S.; Efremova, M.V.; Malinovskaya, J.A.; Semkina, A.S.; Abakumov, M.A. Encapsulins—Bacterial
protein nanocompartments: Structure, properties, and application. Biomolecules 2020, 10, 966. [CrossRef] [PubMed]
154. Kanekiyo, M.; Bu, W.; Gordon, M.; Graham, B.S.; Jeffrey, I.; Nabel, G.J.; Kanekiyo, M.; Bu, W.; Joyce, M.G.; Meng, G.; et al. Rational
Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell 2015, 162, 1090–1100. [CrossRef]
155. Brouwer, P.J.M.; Antanasijevic, A.; Berndsen, Z.; Yasmeen, A.; Fiala, B.; Bijl, T.P.L.; Bontjer, I.; Bale, J.B.; Sheffler, W.; Allen,
J.D.; et al. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein
nanoparticle. Nat. Commun. 2019, 10, 4272. [CrossRef] [PubMed]
156. Marcandalli, J.; Fiala, B.; Ols, S.; Perotti, M.; de van der Schueren, W.; Snijder, J.; Hodge, E.; Benhaim, M.; Ravichandran, R.; Carter,
L.; et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory
Syncytial Virus. Cell 2019, 176, 1420–1431.e17. [CrossRef]
157. Ueda, G.; Antanasijevic, A.; Fallas, J.A.; Sheffler, W.; Copps, J.; Ellis, D.; Hutchinson, G.B.; Moyer, A.; Yasmeen, A.; Tsybovsky, Y.;
et al. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife 2020, 9,
e57659. [CrossRef]
158. Castiñeiras, T.S.; Williams, S.G.; Hitchcock, A.G.; Smith, D.C.E. coli strain engineering for the production of advanced biopharma-
ceutical products. FEMS Microbiol. Lett. 2018, 365, 1–10. [CrossRef] [PubMed]
159. Legastelois, I.; Buffin, S.; Peubez, I.; Mignon, C.; Sodoyer, R.; Werle, B. Non-conventional expression systems for the production of
vaccine proteins and immunotherapeutic molecules. Hum. Vaccines Immunother. 2017, 13, 947–961. [CrossRef]
160. Mahalik, S.; Sharma, A.K.; Mukherjee, K.J. Genome engineering for improved recombinant protein expression in Escherichia coli.
Microb. Cell Fact. 2014, 13, 1–13. [CrossRef]
161. Mignon, C.; Sodoyer, R.; Werle, B. Antibiotic-free selection in biotherapeutics: Now and forever. Pathogens 2015, 4, 157–181.
[CrossRef]
162. Habibi, N.; Mohd Hashim, S.Z.; Norouzi, A.; Samian, M.R. A review of machine learning methods to predict the solubility of
overexpressed recombinant proteins in Escherichia coli. BMC Bioinform. 2014, 15, 134. [CrossRef]
163. Shabani, S.H.; Zakeri, S.; Mortazavi, Y.; Mehrizi, A.A. Immunological evaluation of two novel engineered Plasmodium vivax
circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice. Med. Microbiol.
Immunol. 2019, 208, 731–745. [CrossRef] [PubMed]
164. Cino, J. High-yield protein production from Pichia pastoris yeast: A protocol for benchtop fermentation. Am. Biotechnol. Lab.
1999, 17, 10–13.
165. Tomimoto, K.; Fujita, Y.; Iwaki, T.; Chiba, Y.; Jigami, Y.; Nakayama, K.I.; Nakajima, Y.; Abe, H. Protease-deficient saccharomyces
cerevisiae strains for the synthesis of human-compatible glycoproteins. Biosci. Biotechnol. Biochem. 2013, 77, 2461–2466. [CrossRef]
166. Han, M.; Yu, X. Enhanced expression of heterologous proteins in yeast cells via the modification of N-glycosylation sites.
Bioengineered 2015, 6, 115–118. [CrossRef]
167. Wildt, S.; Gerngross, T.U. The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 2005, 3, 119–128.
[CrossRef] [PubMed]
168. Laurent, J.M.; Young, J.H.; Kachroo, A.H.; Marcotte, E.M. Efforts to make and apply humanized yeast. Brief. Funct. Genom. 2016,
15, 155–163. [CrossRef]
169. Yang, S.; Kuang, Y.; Li, H.; Liu, Y.; Hui, X.; Li, P.; Jiang, Z.; Zhou, Y.; Wang, Y.; Xu, A.; et al. Enhanced Production of Recombinant
Secretory Proteins in Pichia pastoris by Optimizing Kex2 P1′ site. PLoS ONE 2013, 8, e75347. [CrossRef]
170. Love, K.R.; Politano, T.J.; Panagiotou, V.; Jiang, B.; Stadheim, T.A.; Love, J.C. Systematic single-cell analysis of pichia pastoris
reveals secretory capacity limits productivity. PLoS ONE 2012, 7, e37915. [CrossRef] [PubMed]
171. Larsen, S.; Weaver, J.; de Sa Campos, K.; Bulahan, R.; Nguyen, J.; Grove, H.; Huang, A.; Low, L.; Tran, N.; Gomez, S.; et al. Mutant
strains of Pichia pastoris with enhanced secretion of recombinant proteins. Biotechnol. Lett. 2013, 35, 1925–1935. [CrossRef]
172. MacKay, P.; Pasek, M.; Magazin, M.; Kovacic, R.T.; Allet, B.; Stahl, S.; Gilbert, W.; Schaller, H.; Bruce, S.A.; Murray, K. Production
of immunologically active surface antigens of hepatitis B virus by Escherichia coli. Proc. Natl. Acad. Sci. USA 1981, 78, 4510–4514.
[CrossRef] [PubMed]
173. Edman, J.C.; Hallewell, R.A.; Valenzuela, P.; Goodman, H.M.; Rutter, W.J. Synthesis of hepatitis B surface and core antigens in E.
coli. Nature 1981, 291, 503–506. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 29 of 33
174. Burrell, C.J.; Mackay, P.; Greenaway, P.J.; Hofschneider, P.H.; Murray, K. Expression in Escherichia coli of hepatitis B virus DNA
sequences cloned in plasmid pBR322. Nature 1979, 279, 43–47. [CrossRef] [PubMed]
175. Cregg, J.M.; Tschopp, J.F.; Stillman, C.; Siegel, R.; Akong, M.; Craig, W.S.; Buckholz, R.G.; Madden, K.R.; Kellaris, P.A.; Davis, G.R.;
et al. High-level expression and efficient assembly of hepatitis-B surface-antigen in the methylotrophic yeast, Pichia-Pastoris. Nat.
Biotechnol. 1987, 5, 479–485. [CrossRef]
176. Miller, L. A virus vector for genetic engineering in invertebrates. In Genetic Engineering in the Plant Sciences; Panopaulus, N., Ed.;
The University of Chicago Press: Chicago, IL, USA, 1981; pp. 203–222.
177. Cox, M.M. Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30, 1759–1766. [CrossRef]
178. Roelvink, P.W.; Van Meer, M.M.M.; De Kort, C.A.D.; Possee, R.D.; Hammock, B.D.; Vlak, J.M. Dissimilar expression of Autographa
californica multiple nucleocapsid nuclear polyhedrosis virus polyhedrin and p10 genes. J. Gen. Virol. 1992, 73, 1481–1489.
[CrossRef]
179. Tomiya, N.; Narang, S.; Lee, Y.C.; Betenbaugh, M.J. Comparing N-glycan processing in mammalian cell lines to native and
engineered lepidopteran insect cell lines. Glycoconj. J. 2004, 21, 343–360. [CrossRef]
180. Aumiller, J.J.; Mabashi-Asazuma, H.; Hillar, A.; Shi, X.; Jarvis, D.L. A new glycoengineered insect cell line with an inducibly
mammalianized protein N-glycosylation pathway. Glycobiology 2012, 22, 417–428. [CrossRef]
181. Okada, T.; Ihara, H.; Ito, R.; Nakano, M.; Matsumoto, K.; Yamaguchi, Y.; Taniguchi, N.; Ikeda, Y. N-Glycosylation engineering
of lepidopteran insect cells by the introduction of the β1,4-N-acetylglucosaminyltransferase III gene. Glycobiology 2010, 20,
1147–1159. [CrossRef]
182. Palmberger, D.; Wilson, I.B.; Berger, I.; Grabherr, R.; Rendic, D. Sweetbac: A new approach for the production of mammalianised
glycoproteins in insect cells. PLoS ONE 2012, 7, e34226. [CrossRef]
183. Mabashi-Asazuma, H.; Shi, X.; Geisler, C.; Kuo, C.W.; Khoo, K.H.; Jarvis, D.L. Impact of a human CMP-sialic acid transporter on
recombinant glycoprotein sialylation in glycoengineered insect cells. Glycobiology 2013, 23, 199–210. [CrossRef] [PubMed]
184. Yun, E.Y.; Goo, T.W.; Kim, S.W.; Choi, K.H.; Hwang, J.S.; Kang, S.W.; Kwon, O.Y. Galatosylation and sialylation of mammalian
glycoproteins produced by baculovirus-madiated gene expression in insect cells. Biotechnol. Lett. 2005, 27, 1035–1039. [CrossRef]
[PubMed]
185. Mena, J.A.; Kamen, A.A. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev. Vaccines
2011, 10, 1063–1081. [CrossRef] [PubMed]
186. Anassi, E.; Ndefo, U.A. Sipuleucel-T (Provenge) injection the first immunotherapy agent (Vaccine) for hormone-refractory
prostate cancer. Pharm. Ther. 2011, 36, 197–202.
187. U.S. Food and Drug Administration. Available online: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-
products/provenge-sipuleucel-t (accessed on 1 June 2021).
188. Govindarajan, D.; Meschino, S.; Guan, L.; Clements, D.E.; ter Meulen, J.H.; Casimiro, D.R.; Coller, B.A.G.; Bett, A.J. Preclinical
development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman
primates. Vaccine 2015, 33, 4105–4116. [CrossRef]
189. Jenkins, N.; Meleady, P.; Tyther, R.; Murphy, L. Strategies for analysing and improving the expression and quality of recombinant
proteins made in mammalian cells. Biotechnol. Appl. Biochem. 2009, 53, 73–83. [CrossRef]
190. Barone, P.W.; Wiebe, M.E.; Leung, J.C.; Hussein, I.T.M.; Keumurian, F.J.; Bouressa, J.; Brussel, A.; Chen, D.; Chong, M.; Dehghani,
H. Viral contamination in biologic manufacture and implications for emerging therapies. Nat. Biotechnol. 2020, 38, 563–572.
[CrossRef]
191. Barrett, P.N.; Mundt, W.; Kistner, O.; Howard, M.K. Vero cell platform in vaccine production: Moving towards cell culture-based
viral vaccines. Expert Rev. Vaccines 2009, 8, 607–618. [CrossRef]
192. Wippermann, A.; Rupp, O.; Brinkrolf, K.; Hoffrogge, R.; Noll, T. The DNA methylation landscape of Chinese hamster ovary
(CHO) DP-12 cells. J. Biotechnol. 2015, 199, 38–46. [CrossRef]
193. Dorai, H.; Corisdeo, S.; Ellis, D.; Kinney, C.; Chomo, M.; Hawley-Nelson, P.; Moore, G.; Betenbaugh, M.J.; Ganguly, S. Early
prediction of instability of chinese hamster ovary cell lines expressing recombinant antibodies and antibody-fusion proteins.
Biotechnol. Bioeng. 2012, 109, 1016–1030. [CrossRef]
194. Gaillet, B.; Gilbert, R.; Broussau, S.; Pilotte, A.; Malenfant, F.; Mullick, A.; Garnier, A.; Massie, B. High-level recombinant protein
production in CHO cells using lentiviral vectors and the cumate gene-switch. Biotechnol. Bioeng. 2010, 106, 203–215. [CrossRef]
195. Baranyi, L.; Doering, C.B.; Denning, G.; Gautney, R.E.; Harris, K.T.; Trent Spencer, H.; Roy, A.; Zayed, H.; Dropulic, B. Rapid
generation of stable cell lines expressing high levels of erythropoietin, factor VIII, and an antihuman CD20 antibody using
lentiviral vectors. Hum. Gene Ther. Methods 2013, 24, 214–227. [CrossRef] [PubMed]
196. Casales, E.; Aranda, A.; Quetglas, J.I.; Ruiz-Guillen, M.; Rodriguez-Madoz, J.R.; Prieto, J.; Smerdou, C. A novel system for the
production of high levels of functional human therapeutic proteins in stable cells with a Semliki Forest virus noncytopathic vector.
New Biotechnol. 2010, 27, 138–148. [CrossRef] [PubMed]
197. Lee, J.S.; Grav, L.M.; Lewis, N.E.; Kildegaard, H.F. CRISPR/Cas9-mediated genome engineering of CHO cell factories: Application
and perspectives. Biotechnol. J. 2015, 10, 979–994. [CrossRef] [PubMed]
198. Lee, J.S.; Kallehauge, T.B.; Pedersen, L.E.; Kildegaard, H.F. Site-specific integration in CHO cells mediated by CRISPR/Cas9 and
homology-directed DNA repair pathway. Sci. Rep. 2015, 5, 8572. [CrossRef]
199. Worton, R.G.; Ho, C.C.; Duff, C. Chromosome stability in CHO cells. Somatic Cell Genet. 1977, 3, 27–45. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 30 of 33
200. Huang, Y.M.; Hu, W.W.; Rustandi, E.; Chang, K.; Yusuf-Makagiansar, H.; Ryll, T. Maximizing productivity of CHO cell-based
fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog. 2010, 26,
1400–1410. [CrossRef] [PubMed]
201. Sinacore, M.S.; Drapeau, D.; Adamson, S.R. Adaptation of mammalian cells to growth in serum-free media. Mol. Biotechnol. 2000,
15, 249–257. [CrossRef]
202. Luo, H.; Tie, L.; Cao, M.; Hunter, A.K.; Pabst, T.M.; Du, J.; Field, R.; Li, Y.; Wang, W.K. Cathepsin L Causes Proteolytic Cleavage of
Chinese-Hamster-Ovary Cell Expressed Proteins During Processing and Storage: Identification, Characterization, and Mitigation.
Biotechnol. Prog. 2019, 35, e2732. [CrossRef]
203. Laux, H.; Romand, S.; Nuciforo, S.; Farady, C.J.; Tapparel, J.; Buechmann-Moeller, S.; Sommer, B.; Oakeley, E.J.; Bodendorf,
U. Degradation of recombinant proteins by Chinese hamster ovary host cell proteases is prevented by matriptase-1 knockout.
Biotechnol. Bioeng. 2018, 115, 2530–2540. [CrossRef]
204. Lim, A.; Doyle, B.L.; Kelly, G.M.; Reed-Bogan, A.M.; Breen, L.H.; Shamlou, P.A.; Lambooy, P.K. Characterization of a cathepsin D
protease from CHO cell-free medium and mitigation of its impact on the stability of a recombinant therapeutic protein. Biotechnol.
Prog. 2018, 34, 120–129. [CrossRef]
205. Dorai, H.; Santiago, A.; Campbell, M.; Tang, Q.M.; Lewis, M.J.; Wang, Y.; Lu, Q.Z.; Wu, S.L.; Hancock, W. Characterization of the
proteases involved in the N-terminal clipping of glucagon-like-peptide-1-antibody fusion proteins. Biotechnol. Prog. 2011, 27,
220–231. [CrossRef] [PubMed]
206. Clincke, M.; Guedon, E.; Yen, F.T.; Ogier, V.; Goergen, J.-L. Characterization of metalloprotease and serine protease activities in
batch CHO cell cultures: Control of human recombinant IFN-γ proteolysis by addition of iron citrate. BMC Proc. 2011, 5, P115.
[CrossRef]
207. Robert, F.; Bierau, H.; Rossi, M.; Agugiaro, D.; Soranzo, T.; Broly, H.; Mitchell-Logean, C. Degradation of an Fc-fusion recombinant
protein by host cell proteases: Identification of a CHO cathepsin D protease. Biotechnol. Bioeng. 2009, 104, 1132–1141. [CrossRef]
[PubMed]
208. Li, S.W.; Wright, M.; Healey, J.F.; Hutchinson, J.M.; O’Rourke, S.; Mesa, K.A.; Lollar, P.; Berman, P.W. Gene editing in CHO cells to
prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens. PLoS ONE 2020,
15, e0233866. [CrossRef]
209. Fontana, D.; Kratje, R.; Etcheverrigaray, M.; Prieto, C. Rabies virus-like particles expressed in HEK293 cells. Vaccine 2014, 32,
2799–2804. [CrossRef] [PubMed]
210. He, L.; Chaudhary, A.; Lin, X.; Sou, C.; Alkutkar, T.; Kumar, S.; Ngo, T.; Kosviner, E.; Ozorowski, G.; Stanfield, R.L.; et al.
Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus
vaccines. Nat. Commun. 2021, 12, 1–18. [CrossRef] [PubMed]
211. Autheman, D.; Crosnier, C.; Clare, S.; Goulding, D.A.; Brandt, C.; Harcourt, K.; Tolley, C.; Galaway, F.; Khushu, M.; Ong, H.; et al.
An invariant Trypanosoma vivax vaccine antigen induces protective immunity. Nature 2021, 595, 96–100. [CrossRef] [PubMed]
212. Slon-Campos, J.L.; Dejnirattisai, W.; Jagger, B.W.; López-Camacho, C.; Wongwiwat, W.; Durnell, L.A.; Winkler, E.S.; Chen,
R.E.; Reyes-Sandoval, A.; Rey, F.A.; et al. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate
antibody-dependent enhancement of dengue infection. Nat. Immunol. 2019, 20, 1291–1298. [CrossRef]
213. Kis, Z.; Shattock, R.; Shah, N.; Kontoravdi, C. Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. Biotechnol. J.
2019, 14, 1–36. [CrossRef]
214. Waye, A.; Jacobs, P.; Schryvers, A.B. Vaccine development costs: A review. Expert Rev. Vaccines 2013, 12, 1495–1501. [CrossRef]
[PubMed]
215. Plotkin, S.; Robinson, J.M.; Cunningham, G.; Iqbal, R.; Larsen, S. The complexity and cost of vaccine manufacturing—An overview.
Vaccine 2017, 35, 4064–4071. [CrossRef] [PubMed]
216. Wilson, P. Giving Developing Countries the Best Shot: An Overview of Vaccine Access and R&D; Campaign for Access to Essential
Medicines: Geneva, Switzerland, 2010.
217. Pronker, E.S.; Weenen, T.C.; Commandeur, H.; Claassen, E.H.J.H.M.; Osterhaus, A.D.M.E. Risk in Vaccine Research and
Development Quantified. PLoS ONE 2013, 8, e57755. [CrossRef] [PubMed]
218. Qadri, F. Understanding vaccine development. In Proceedings of the GAVI Alliance Partner’s Forum, Dar Es Salaam, Tanzania, 7
December 2012.
219. Wen, E.P.; Ellis, R.; Pujar, N.S. Vaccine Development and Manufacturing; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2014.
220. Datla, M. Understanding Vaccine Manufacturing. In Proceedings of the GAVI Alliance Partner’s Forum, Dar Es Salaam, Tanzania,
7 December 2012.
221. Vidor, E.; Soubeyrand, B. Manufacturing DTaP-based combination vaccines: Industrial challenges around essential public health
tools. Expert Rev. Vaccines 2016, 15, 1575–1582. [CrossRef] [PubMed]
222. Shane, S. Impact of E. coli on profitable egg production. Egg Ind. 2009, 114, 8–12.
223. Retallack, D.M.; Jin, H.; Chew, L. Reliable protein production in a Pseudomonas fluorescens expression system. Protein Expr.
Purif. 2012, 81, 157–165. [CrossRef] [PubMed]
224. Gruber, S.; Schwab, H.; Koefinger, P. Versatile plasmid-based expression systems for Gram-negative bacteria-General essentials
exemplified with the bacterium Ralstonia eutropha H16. New Biotechnol. 2015, 32, 552–558. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 31 of 33
225. Bermúdez-Humarán, L.G.; Aubry, C.; Motta, J.P.; Deraison, C.; Steidler, L.; Vergnolle, N.; Chatel, J.M.; Langella, P. Engineering
lactococci and lactobacilli for human health. Curr. Opin. Microbiol. 2013, 16, 278–283. [CrossRef]
226. Van Baarlen, P.; Wells, J.M.; Kleerebezem, M. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends
Immunol. 2013, 34, 208–215. [CrossRef]
227. Ribelles, P.; Benbouziane, B.; Langella, P.; Suárez, J.E.; Bermúdez-Humarán, L.G.; Riazi, A. Protection against human papillo-
mavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface.
Appl. Microbiol. Biotechnol. 2013, 97, 1231–1239. [CrossRef]
228. De Lúcia Hernani, M.; Ferreira, P.C.D.; Ferreira, D.M.; Miyaji, E.N.; Ho, P.L.; Oliveira, M.L.S. Nasal immunization of mice with
Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal
nasopharyngeal colonization in mice. FEMS Immunol. Med. Microbiol. 2011, 62, 263–272. [CrossRef]
229. Mohamadzadeh, M.; Durmaz, E.; Zadeh, M.; Pakanati, K.C.; Gramarossa, M.; Cohran, V.; Klaenhammer, T.R. Targeted expression
of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future Microbiol. 2010, 5, 1289–1296. [CrossRef]
[PubMed]
230. Shi, S.H.; Yang, W.T.; Yang, G.L.; Cong, Y.L.; Huang, H.B.; Wang, Q.; Cai, R.P.; Ye, L.P.; Hu, J.T.; Zhou, J.Y.; et al. Immunoprotection
against influenza virus H9N2 by the oral administration of recombinant Lactobacillus plantarum NC8 expressing hemagglutinin
in BALB/c mice. Virology 2014, 464–465, 166–176. [CrossRef] [PubMed]
231. Trombert, A. Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: The future of vaccination? Benef.
Microbes 2015, 6, 313–324. [CrossRef] [PubMed]
232. Wells, J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu. Rev. Food Sci. Technol. 2011, 2,
423–445. [CrossRef]
233. Roland, K.L.; Tinge, S.A.; Killeen, K.P.; Kochi, S.K. Recent advances in the development of live, attenuated bacterial vectors. Curr.
Opin. Mol. Ther. 2005, 7, 62–72. [PubMed]
234. Toomey, N.; Bolton, D.; Fanning, S. Characterisation and transferability of antibiotic resistance genes from lactic acid bacteria
isolated from Irish pork and beef abattoirs. Res. Microbiol. 2010, 161, 127–135. [CrossRef] [PubMed]
235. Bosma, T.; Kanninga, R.; Neef, J.; Audouy, S.A.L.; Van Roosmalen, M.L.; Steen, A.; Buist, G.; Kok, J.; Kuipers, O.P.; Robillard, G.;
et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl. Environ. Microbiol.
2006, 72, 880–889. [CrossRef]
236. Shin, M.K.; Yoo, H.S. Animal vaccines based on orally presented yeast recombinants. Vaccine 2013, 31, 4287–4292. [CrossRef]
[PubMed]
237. Vieira Gomes, A.; Souza Carmo, T.; Silva Carvalho, L.; Mendonça Bahia, F.; Parachin, N. Comparison of Yeasts as Hosts for
Recombinant Protein Production. Microorganisms 2018, 6, 38. [CrossRef]
238. Bill, R.M. Recombinant protein subunit vaccine synthesis in microbes: A role for yeast? J. Pharm. Pharmacol. 2015, 67, 319–328.
[CrossRef] [PubMed]
239. Curti, E.; Kwityn, C.; Zhan, B.; Gillespie, P.; Brelsford, J.; Deumic, V.; Plieskatt, J.; Rezende, W.C.; Tsao, E.; Kalampanayil, B.; et al.
Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein.
Hum. Vaccin. Immunother. 2013, 9, 2342–2350. [CrossRef] [PubMed]
240. Lin, G.J.; Liu, T.Y.; Tseng, Y.Y.; Chen, Z.W.; You, C.C.; Hsuan, S.L.; Chien, M.S.; Huang, C. Yeast-expressed classical swine fever
virus glycoprotein E2 induces a protective immune response. Vet. Microbiol. 2009, 139, 369–374. [CrossRef]
241. Kumar, R.; Kumar, P. Yeast-based vaccines: New perspective in vaccine development and application. FEMS Yeast Res. 2019, 19,
1–22. [CrossRef] [PubMed]
242. Piraine, R.E.A.; Gonçalves, V.S.; dos Santos Junior, A.G.; Cunha, R.C.; de Albuquerque, P.M.M.; Conrad, N.L.; Leite, F.P.L.
Expression cassette and plasmid construction for Yeast Surface Display in Saccharomyces cerevisiae. Biotechnol. Lett. 2021, 43,
1649–1657. [CrossRef]
243. Habersetzer, F.; Baumert, T.F.; Stoll-Keller, F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic
HCV infection. Curr. Opin. Mol. Ther. 2009, 11, 456–462. [PubMed]
244. Jacob, D.; Ruffie, C.; Dubois, M.; Combredet, C.; Amino, R.; Formaglio, P.; Gorgette, O.; Pehau-Arnaudet, G.; Guery, C.; Puijalon,
O.; et al. Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize
Plasmodium antigens. PLoS ONE 2014, 9, e86658. [CrossRef]
245. Huang, H.; Ostroff, G.R.; Lee, C.K.; Specht, C.A.; Levitz, S.M. Characterization and optimization of the glucan particle-based
vaccine platform. Clin. Vaccine Immunol. 2013, 20, 1585–1591. [CrossRef]
246. Gao, T.; Ren, Y.; Li, S.; Lu, X.; Lei, H. Immune response induced by oral administration with a Saccharomyces cerevisiae-based
SARS-CoV-2 vaccine in mice. Microb. Cell Fact. 2021, 20, 1–10. [CrossRef]
247. Cao, D.; Wu, H.; Li, Q.; Sun, Y.; Liu, T.; Fei, J.; Zhao, Y.; Wu, S.; Hu, X.; Li, N. Expression of recombinant human lysozyme in egg
whites of transgenic hens. PLoS ONE 2015, 10, e0118626. [CrossRef]
248. Herron, L.R.; Pridans, C.; Turnbull, M.L.; Smith, N.; Lillico, S.; Sherman, A.; Gilhooley, H.J.; Wear, M.; Kurian, D.; Papadakos, G.;
et al. A chicken bioreactor for efficient production of functional cytokines. BMC Biotechnol. 2018, 18, 82. [CrossRef]
249. Adachi, K.; Takama, K.; Tsukamoto, M.; Inai, M.; Handharyani, E.; Hiroi, S.; Tsukamoto, Y. Ostrich produce cross-reactive
neutralization antibodies against pandemic influenza virus A/H1N1 following immunization with a seasonal influenza vaccine.
Exp. Ther. Med. 2011, 2, 41–45. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1072 32 of 33
250. Wang, Y.; Zhao, S.; Bai, L.; Fan, J.; Liu, E. Expression Systems and Species Used for Transgenic Animal Bioreactors. Transgenic Res.
2013, 580463. [CrossRef]
251. European Food Safety Authority (EFSA). Guidance on the environmental risk assessment of genetically modified animals. EFSA
Panel on Genetically Modified Organisms (GMOs). EFSA J. 2013, 11, 3200. [CrossRef]
252. Vàzquez-Salat, N.; Houdebine, L.M. Will GM animals follow the GM plant fate? Transgenic Res. 2013, 22, 5–13. [CrossRef]
[PubMed]
253. Vàzquez-Salat, N.; Salter, B.; Smets, G.; Houdebine, L.M. The current state of GMO governance: Are we ready for GM animals?
Biotechnol. Adv. 2012, 30, 1336–1343. [CrossRef]
254. Houdebine, L.M. Production of pharmaceutical proteins by transgenic animals. Rev. Sci. Tech. 2018, 37, 131–139. [CrossRef]
255. Konkle, B.A.; Bauer, K.A.; Weinstein, R.; Greist, A.; Holmes, H.E.; Bonfiglio, J. Use of recombinant human antithrombin in patients
with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003, 43, 390–394. [CrossRef] [PubMed]
256. Hunter, P. The prospects for recombinant proteins from transgenic animals. EMBO Rep. 2019, 20, 1–3. [CrossRef]
257. Behboodi, E.; Ayres, S.L.; Memili, E.; O’Coin, M.; Chen, L.H.; Reggio, B.C.; Landry, A.M.; Gavin, W.G.; Meade, H.M.; Godke, R.A.;
et al. Health and reproductive profiles of malaria antigen-producing transgenic goats derived by somatic cell nuclear transfer.
Cloning Stem Cells 2005, 7, 107–118. [CrossRef] [PubMed]
258. Maeda, S.; Kawai, T.; Obinata, M.; Fujiwara, H.; Horiuchi, T.; Saeki, Y.; Sato, Y.; Furusawa, M. Production of human α-interferon
in silkworm using a baculovirus vecto. Nature 1985, 315, 592–594. [CrossRef]
259. He, Q.; Cao, Z.; Wang, P.; Lu, Q.; Zheng, H.; Sun, J. Efficient application of a baculovirus-silkworm larvae expression system for
obtaining porcine circovirus type 2 virus-like particles for a vaccine. Arch. Virol. 2020, 165, 2301–2309. [CrossRef] [PubMed]
260. Pérez-Martín, E.; Gómez-Sebastián, S.; Argilaguet, J.M.; Sibila, M.; Fort, M.; Nofrarías, M.; Kurtz, S.; Escribano, J.M.; Segalés,
J.; Rodríguez, F. Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in
Trichoplusia ni-larvae. Vaccine 2010, 28, 2340–2349. [CrossRef] [PubMed]
261. Escribano-Romero, E.; Gamino, V.; Merino-Ramos, T.; Blázquez, A.B.; Martín-Acebes, M.A.; de Oya, N.J.; Gutiérrez-Guzmán, A.V.;
Escribano, J.M.; Höfle, U.; Saiz, J.C. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection
after immunization with WNV recombinant envelope protein E (rE). Vaccine 2013, 31, 4523–4527. [CrossRef] [PubMed]
262. Pérez-Filgueira, D.M.; Resino-Talaván, P.; Cubillos, C.; Angulo, I.; Barderas, M.G.; Barcena, J.; Escribano, J.M. Development of a
low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology 2007, 364, 422–430. [CrossRef]
263. Gomez-Casado, E.; Gomez-Sebastian, S.; Núñez, M.C.; Lasa-Covarrubias, R.; Martínez-Pulgarín, S.; Escribano, J.M. Insect larvae
biofactories as a platform for influenza vaccine production. Protein Expr. Purif. 2011, 79, 35–43. [CrossRef]
264. Millán, A.F.S.; Gómez-Sebastián, S.; Nuñez, M.C.; Veramendi, J.; Escribano, J.M. Human papillomavirus-like particles vaccine
efficiently produced in a non-fermentative system based on insect larva. Protein Expr. Purif. 2010, 74, 1–8. [CrossRef]
265. Escribano, J.M.; Cid, M.; Reytor, E.; Alvarado, C.; Nuñez, M.C.; Martínez-Pulgarín, S.; Dalton, R.M. Chrysalises as natural
production units for recombinant subunit vaccines. J. Biotechnol. X 2020, 6, 100019. [CrossRef]
266. Zhang, X.; Shen, W.; Lu, Y.; Zheng, X.; Xue, R.; Cao, G.; Pan, Z.; Gong, C. Expression of UreB and HspA of helicobacter pylori in
silkworm pupae and identification of its immunogenicity. Mol. Biol. Rep. 2011, 38, 3173–3180. [CrossRef]
267. Gong, Z.; Jin, Y.; Zhang, Y. Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects
against autoimmune diabetes. J. Biotechnol. 2005, 119, 93–105. [CrossRef] [PubMed]
268. Xu, J.; Towler, M.; Weathers, P.J. Platforms for Plant-Based Protein Production. In Bioprocessing of Plant In Vitro System; Springer:
Berlin/Heidelberg, Germany, 2018; pp. 509–548. ISBN 9783319546001.
269. Bosch, D.; Schots, A. Plant glycans: Friend or foe in vaccine development? Expert Rev. Vaccines 2010, 9, 835–842. [CrossRef]
[PubMed]
270. Loos, A.; Steinkellner, H. Plant glyco-biotechnology on the way to synthetic biology. Front. Plant Sci. 2014, 5, 1–10. [CrossRef]
[PubMed]
271. Ruhlman, T.; Verma, D.; Samson, N.; Daniell, H. The role of heterologous chloroplast sequence elements in transgene integration
and expression. Plant Physiol. 2010, 152, 2088–2104. [CrossRef] [PubMed]
272. Oey, M.; Lohse, M.; Kreikemeyer, B.; Bock, R. Exhaustion of the chloroplast protein synthesis capacity by massive expression of a
highly stable protein antibiotic. Plant J. 2009, 57, 436–445. [CrossRef]
273. Waheed, M.T.; Sameeullah, M.; Khan, F.A.; Syed, T.; Ilahi, M.; Gottschamel, J.; Lössl, A.G. Need of cost-effective vaccines in
developing countries: What plant biotechnology can offer? SpringerPlus 2016, 5, 1–9. [CrossRef]
274. Lössl, A.G.; Waheed, M.T. Chloroplast-derived vaccines against human diseases: Achievements, challenges and scopes. Plant
Biotechnol. J. 2011, 9, 527–539. [CrossRef]
275. Komarova, T.V.; Baschieri, S.; Donini, M.; Marusic, C.; Benvenuto, E.; Dorokhov, Y.L. Transient expression systems for plant-
derived biopharmaceuticals. Expert Rev. Vaccines 2010, 9, 859–876. [CrossRef] [PubMed]
276. Rybicki, E.P. Plant-produced vaccines: Promise and reality. Drug Discov. Today 2009, 14, 16–24. [CrossRef] [PubMed]
277. Shim, B.S.; Hong, K.J.; Maharjan, P.M.; Choe, S. Plant factory: New resource for the productivity and diversity of human and
veterinary vaccines. Clin. Exp. Vaccine Res. 2019, 8, 136–139. [CrossRef] [PubMed]
278. Qiu, X.; Wong, G.; Audet, J.; Bello, A.; Fernando, L.; Alimonti, J.B.; Fausther-Bovendo, H.; Wei, H.; Aviles, J.; Hiatt, E.; et al.
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514, 47–53. [CrossRef]
Biomolecules 2021, 11, 1072 33 of 33
279. Rosales-Mendoza, S.; Nieto-Gómez, R.; Angulo, C. A perspective on the development of plant-made vaccines in the fight against
ebola virus. Front. Immunol. 2017, 8, 1–13. [CrossRef] [PubMed]
280. Tusé, D.; Tu, T.; McDonald, K.A. Manufacturing economics of plant-made biologics: Case studies in therapeutic and industrial
enzymes. Biomed Res. Int. 2014, 256135. [CrossRef]
281. Tusé, D.; Ku, N.; Bendandi, M.; Becerra, C.; Collins, R.; Langford, N.; Sancho, S.I.; López-Díaz De Cerio, A.; Pastor, F.; Kandzia,
R.; et al. Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma.
Biomed Res. Int. 2015, 648143. [CrossRef]
282. Alam, A.; Jiang, L.; Kittleson, G.A.; Steadman, K.D.; Nandi, S.; Fuqua, J.L.; Palmer, K.E.; Tusé, D.; McDonald, K.A. Technoeconomic
Modeling of Plant-Based Griffithsin Manufacturing. Front. Bioeng. Biotechnol. 2018, 6, 102. [CrossRef]
283. Twyman, R.M.; Stoger, E.; Schillberg, S.; Christou, P.; Fischer, R. Molecular farming in plants: Host systems and expression
technology. Trends Biotechnol. 2003, 21, 570–578. [CrossRef] [PubMed]
284. Xu, J.; Zhang, N. On the way to commercializing plant cell culture platform for biopharmaceuticals: Present status and prospect.
Pharm. Bioprocess. 2014, 2, 499–518. [CrossRef] [PubMed]
285. Fischer, R.; Schillberg, S.; Hellwig, S.; Twyman, R.M.; Drossard, J. GMP issues for recombinant plant-derived pharmaceutical
proteins. Biotechnol. Adv. 2012, 30, 434–439. [CrossRef]
286. Ratner, M. Pfizer stakes a claim in plant cell-made biopharmaceuticals. Nat. Biotechnol. 2010, 28, 107–108. [CrossRef]
287. Shaaltiel, Y.; Bartfeld, D.; Hashmueli, S.; Baum, G.; Brill-Almon, E.; Galili, G.; Dym, O.; Boldin-Adamsky, S.A.; Silman, I.; Sussman,
J.L.; et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease
using a plant cell system. Plant Biotechnol. J. 2007, 5, 579–590. [CrossRef]
288. Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014, 32, 992–1000. [CrossRef]
289. Ward, B.J.; Makarkov, A.; Séguin, A.; Pillet, S.; Trépanier, S.; Dhaliwall, J.; Libman, M.D.; Vesikari, T.; Landry, N. Efficacy,
immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and
older adults (≥65 years): Two multicentre, randomised phase 3 trials. Lancet 2020, 396, 1491–1503. [CrossRef]
290. Kolotilin, I.; Topp, E.; Cox, E.; Devriendt, B.; Conrad, U.; Joensuu, J.; Stöger, E.; Warzecha, H.; McAllister, T.; Potter, A.; et al.
Plant-based solutions for veterinary immunotherapeutics and prophylactics. Vet. Res. 2014, 45, 117. [CrossRef]
291. Takeyama, N.; Kiyono, H.; Yuki, Y. Plant-based vaccines for animals and humans: Recent advances in technology and clinical
trials. Ther. Adv. Vaccines 2015, 3, 139–154. [CrossRef] [PubMed]
292. Margolin, E.; Chapman, R.; Williamson, A.L.; Rybicki, E.P.; Meyers, A.E. Production of complex viral glycoproteins in plants as
vaccine immunogens. Plant Biotechnol. J. 2018, 16, 1531–1545. [CrossRef]
293. Rosales-Mendoza, S.; Solís-Andrade, K.I.; Márquez-Escobar, V.A.; González-Ortega, O.; Bañuelos-Hernandez, B. Current advances
in the algae-made biopharmaceuticals field. Expert Opin. Biol. Ther. 2020, 20, 751–766. [CrossRef] [PubMed]
294. Lindh, I.; Bråve, A.; Hallengärd, D.; Hadad, R.; Kalbina, I.; Strid, Å.; Andersson, S. Oral delivery of plant-derived HIV-1 p24
antigen in low doses shows a superior priming effect in mice compared to high doses. Vaccine 2014, 32, 2288–2293. [CrossRef]
295. Specht, E.A.; Mayfield, S.P. Algae-based oral recombinant vaccines. Front. Microbiol. 2014, 5, 1–7. [CrossRef]
296. Dreesen, I.A.J.; Charpin-El Hamri, G.; Fussenegger, M. Heat-stable oral alga-based vaccine protects mice from Staphylococcus
aureus infection. J. Biotechnol. 2010, 145, 273–280. [CrossRef] [PubMed]
297. Hempel, F.; Maier, U.G. An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency.
Microb. Cell Fact. 2012, 11, 2–7. [CrossRef]
298. Bayne, A.C.V.; Boltz, D.; Owen, C.; Betz, Y.; Maia, G.; Azadi, P.; Archer-Hartmann, S.; Zirkle, R.; Lippmeier, J.C. Vaccination
against Influenza with Recombinant Hemagglutinin Expressed by Schizochytrium sp. Confers Protective Immunity. PLoS ONE
2013, 8, e61790. [CrossRef]
299. Márquez-Escobar, V.A.; Bañuelos-Hernández, B.; Rosales-Mendoza, S. Expression of a Zika virus antigen in microalgae: Towards
mucosal vaccine development. J. Biotechnol. 2018, 282, 86–91. [CrossRef]
300. Feng, S.; Feng, W.; Zhao, L.; Gu, H.; Li, Q.; Shi, K.; Guo, S.; Zhang, N. Preparation of transgenic Dunaliella salina for immunization
against white spot syndrome virus in crayfish. Arch. Virol. 2014, 159, 519–525. [CrossRef]
